1
|
Mussina K, Kuanova B, Syssoyev D, Gaipov A, Poddighe D, Shaikhyzada K, Aimyshev T, Galiyeva D. Epidemiology of pediatric hematological malignancies in Kazakhstan: Data from Unified National Electronic Healthcare System 2014-2021. Eur J Pediatr 2024; 183:1683-1691. [PMID: 38214809 DOI: 10.1007/s00431-023-05412-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/08/2023] [Revised: 12/20/2023] [Accepted: 12/23/2023] [Indexed: 01/13/2024]
Abstract
We aimed to describe incidence and all-cause mortality of hematological pediatric malignancies (leukemia and lymphomas) in Kazakhstan based on nationwide large-scale healthcare data from the Unified National Electronic Healthcare System (UNEHS) for the 2014-2021 year period. The cohort included data of patients less than 18 years old with the diagnosis of hematological malignancies registered in the UNEHS (inpatient and outpatient registries) for the year period 2014-2021. Descriptive statistics were conducted to indicate socio-demographic characteristics of the cohort. Incidence and all-cause mortality were calculated per 100,000 population. Cox proportional hazard regression analysis was performed to investigate the association between determinants with the all-cause mortality. The total cohort consisted of 3357 children with leukemia and 1474 children with lymphomas. The mean age at diagnosis of leukemia and lymphomas was 7.3 ± 4.7 and 9.9 ± 4.9 years, respectively. The incidence rate of hematological malignancies was 6.8 per 100,000 in 2021. Patients with ALL had a higher incidence rate than patients with AML (3.4 and 1.2 per 100,000 in 2021, respectively). The incidence rate of HL and NHL was relatively similar which varied from 0.6 to 2.6 per 100,000 in 2014-2021. All-cause mortality of pediatric hematological malignancies varied from 1.1 to 1.5 per 100,000 in 2014-2021, with the peak in 2016 (1.7 per 100,000). Younger age is significantly associated with increased risk of all-cause mortality in children with AML. CONCUSION Patients with ALL had a higher incidence rate than patients with AML. The incidence rate of HL and NHL was relatively similar. All-cause mortality rates for leukemia and lymphomas were quite stable during the study period. Younger age is significantly associated with increased all-cause mortality among AML patients. However, there is no significant association of age with all-cause mortality among ALL, HL and NHL. In order to obtain more reliable data and analysis on pediatric (hematological) malignancies, specific registries for childhood tumors (including detailed information on relapses, treatments, short and long-term side effects, and specific death causes) should be implemented. WHAT IS KNOWN • Leukemias and lymphomas together account for around 45% of all pediatric malignancies. • Lymphoma accounts for 12% of all childhood malignancies; non-Hodgkin's lymphomas (NHL) are more frequent than Hodgkin's lymphomas (HL). WHAT IS NEW • The incidence rate of ALL was higher than the incidence rate of AML throughout the whole study period, whereas all-cause mortality of ALL and AML was quite stable. • According to Cox PH analysis, younger age (0-5 years old) was associated with a higher risk of death among AML children compared to older children, and no significant association of age was observed with all-cause mortality among ALL and lymphomas.
Collapse
Affiliation(s)
- Kamilla Mussina
- Department of Medicine, Nazarbayev University School of Medicine (NUSOM), Kerey and Zhanibek Khans Street 5/1, 010000, Astana, Kazakhstan
| | - Bota Kuanova
- Department of Medicine, Nazarbayev University School of Medicine (NUSOM), Kerey and Zhanibek Khans Street 5/1, 010000, Astana, Kazakhstan
| | - Dmitriy Syssoyev
- Department of Medicine, Nazarbayev University School of Medicine (NUSOM), Kerey and Zhanibek Khans Street 5/1, 010000, Astana, Kazakhstan
| | - Abduzhappar Gaipov
- Department of Medicine, Nazarbayev University School of Medicine (NUSOM), Kerey and Zhanibek Khans Street 5/1, 010000, Astana, Kazakhstan
- Clinical Academic Department of Internal Medicine, University Medical Center (UMC), Astana, Kazakhstan
| | - Dimitri Poddighe
- Department of Medicine, Nazarbayev University School of Medicine (NUSOM), Kerey and Zhanibek Khans Street 5/1, 010000, Astana, Kazakhstan
- Clinical Academic Department of Pediatrics, National Research Center for Maternal and Child Health, University Medical Center (UMC), Astana, Kazakhstan
| | - Kundyz Shaikhyzada
- Program of Pediatric Solid Oncology, Clinical Academic Department of Pediatrics, National Research Center for Maternal and Child Health, University Medical Center (UMC), Astana, Kazakhstan
| | - Temirgali Aimyshev
- Department of Medicine, Nazarbayev University School of Medicine (NUSOM), Kerey and Zhanibek Khans Street 5/1, 010000, Astana, Kazakhstan
| | - Dinara Galiyeva
- Department of Medicine, Nazarbayev University School of Medicine (NUSOM), Kerey and Zhanibek Khans Street 5/1, 010000, Astana, Kazakhstan.
| |
Collapse
|
2
|
de Smith AJ, Jiménez-Morales S, Mejía-Aranguré JM. The genetic risk of acute lymphoblastic leukemia and its implications for children of Latin American origin. Front Oncol 2024; 13:1299355. [PMID: 38264740 PMCID: PMC10805326 DOI: 10.3389/fonc.2023.1299355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2023] [Accepted: 12/12/2023] [Indexed: 01/25/2024] Open
Abstract
Acute lymphoblastic leukemia (ALL) is the most common cancer in children, and disproportionately affects children of Hispanic/Latino ethnicity in the United States, who have the highest incidence of disease compared with other racial/ethnic groups. Incidence of childhood ALL is similarly high in several Latin American countries, notably in Mexico, and of concern is the rising incidence of childhood ALL in some Hispanic/Latino populations that may further widen this disparity. Prior studies have implicated common germline genetic variants in the increased risk of ALL among Hispanic/Latino children. In this review, we describe the known disparities in ALL incidence as well as patient outcomes that disproportionately affect Hispanic/Latino children across the Americas, and we focus on the role of genetic variation as well as Indigenous American ancestry in the etiology of these disparities. Finally, we discuss future avenues of research to further our understanding of the causes of the disparities in ALL incidence and outcomes in children of Latin American origin, which will be required for future precision prevention efforts.
Collapse
Affiliation(s)
- Adam J. de Smith
- Center for Genetic Epidemiology, Department of Population and Public Health Sciences, University of Southern California Keck School of Medicine, Los Angeles, CA, United States
- USC Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States
| | - Silvia Jiménez-Morales
- Laboratorio de Innovación y Medicina de Precisión, Núcleo A, Instituto Nacional de Medicina Genómica, Ciudad de México, Mexico
| | - Juan Manuel Mejía-Aranguré
- Laboratorio de Genómica Funcional del Cáncer, Instituto Nacional de Medicina Genómica, Ciudad de México, Mexico
- Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, Mexico
| |
Collapse
|
3
|
Morosini F, Silveira A, Arias V, Castillo L. Incidence, Mortality and Survival of Pediatric Cancer in Uruguay 2011-2015. REVISTA BRASILEIRA DE CANCEROLOGIA 2023. [DOI: 10.32635/2176-9745.rbc.2023v69n1.3054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023] Open
Abstract
Introduction: Childhood cancer is a small proportion of all cancers but is still a major public health problem. Objective: To describe the 5-year incidence and mortality rates and net survival of childhood cancer in Uruguay. Method: Data on all malignant tumors diagnosed in children aged 0-14 were included for the period 2011-2015, obtained from the National Pediatric Registry of Cancer and from the Ministry of Health Mortality Registry, classified according to the International Classification of Childhood Cancer (ICCC-3). Information on the total population was obtained from national census records. Follow up was made until December 2020. Results: The standardized incidence rate was 128/million children per year. The distribution of the disease was similar to developed countries. The overall mortality rate was 28.2/million, with a net overall survival of 79.6% for the total population. Conclusion: Childhood cancer incidence in Uruguay is similar to developed countries. Progress in diagnosis and care have improved survival immensely, but efforts must continue to keep this trend and ameliorate the outcomes.
Collapse
|
4
|
Monárrez‐Espino J, Romero‐Rodriguez L, Escamilla‐Asiain G, Ellis‐Irigoyen A, Cubría‐Juárez MDP, Sematimba D, Rodríguez‐Galindo C, Vega‐Vega L. Survival estimates of childhood malignancies treated at the Mexican telethon pediatric oncology hospital. Cancer Rep (Hoboken) 2023; 6:e1702. [PMID: 36054813 PMCID: PMC9939997 DOI: 10.1002/cnr2.1702] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Revised: 07/08/2022] [Accepted: 07/20/2022] [Indexed: 11/06/2022] Open
Abstract
BACKGROUND Pediatric cancer incidence in Mexico is ~160/million/year with leukemias making 49.8% of the cases. While survival rates have been reported in various Mexican studies, no data is available from the Telethon Pediatric Oncology Hospital-HITO, a nonprofit private institution specialized exclusively in comprehensive pediatric oncology care in the country that closely follows high-income countries' advanced standards of cancer care. AIM To determine overall survival (OS) and relapse-free survival (RFS) in patients treated at HITO between December 2013 and February 2018. METHODS AND RESULTS Secondary analysis of data extracted from medical records. It included 286 children aged 0-17 years diagnosed with various cancers grouped into three categories based on location: (1) Acute lymphoblastic leukemia (ALL), (2) tumors within the central nervous system (TWCNS), and (3) tumors outside the CNS (TOCNS). OS and RFS rates for patients who completed 1 (n = 230) and 3 (n = 132) years of follow-up after admission were computed by sex, age, and cancer location, and separately for a subsample (1-year = 191, 3-years = 110) who fulfilled the HITO criteria (no prior treatment, underwent surgery/chemotherapy when indicated, and initiated therapy). TOCNS accounted for 45.1%, but ALL was the most frequent single diagnosis with 28%. Three-year OS for patients with ALL, TWCNS, and TOCNS who fulfilled the HITO criteria were 91.9%, 86.7%, and 79.3%, respectively; for 3-year RFS these were 89.2%, 60%, and 72.4%. Boys showed slightly higher OS and RFS, but no major differences or trends were seen by age group. CONCLUSION This study sets a relevant reference in terms of survival and relapse for children with cancer in Mexico treated at a private oncology center that uses a comprehensive and integrated therapeutic model.
Collapse
Affiliation(s)
- Joel Monárrez‐Espino
- Department of Health Research, Christus Muguerza del Parque HospitalUniversity of MonterreyChihuahuaMexico
- PhD Program in Molecular Medicine, Human Medicine and Health Sciences Academic UnitZacatecas Autonomous UniversityZacatecasMexico
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Huang J, Chan SC, Ngai CH, Lok V, Zhang L, Lucero‐Prisno DE, Xu W, Zheng Z, Elcarte E, Withers M, Wong MCS. Global incidence, mortality and temporal trends of cancer in children: A joinpoint regression analysis. Cancer Med 2022; 12:1903-1911. [PMID: 35822443 PMCID: PMC9883415 DOI: 10.1002/cam4.5009] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Revised: 06/17/2022] [Accepted: 06/23/2022] [Indexed: 02/01/2023] Open
Abstract
BACKGROUND/METHODS The Cancer Incidence in Five Continents Time Trends, Nordic Cancer Registries, Surveillance, Epidemiology and End Results, WHO Mortality databases were assessed to extract the Age-Standardised Rates (ASR) of cancer incidence and mortality among children aged 0-14 years old. By using the ASRs, the country-specific Average Annual Percentage Change (AAPC) and its corresponding 95% confidence interval (CI) were calculated to determine the epidemiological cancer trend. RESULTS In 2020, the highest incidence of childhood cancer was found in countries with higher Human Development Index (HDI) (ASR = 15.7), yet the highest mortality was found in countries with lower HDIs (ASR = 4.8). As for incidence, seven countries had positive AAPC among boys; Slovakia (AAPC2001-2010 = 4.98, 95% CI [1.66-8.40]), Ecuador (AAPC2003-2012 = 4.07, 95% CI [0.67-7.59]) and Thailand (AAPC2003-2012 = 3.69, 95% CI [0.37-7.11]) had the highest AAPC. Among girls, three countries had positive AAPC, which included Belarus (AAPC2003-2012 = 3.18, 95% CI [1.11, 5.29]), Canada (AAPC2003-2012 = 2.83, 95% CI [1.60, 4.07]) and Korea (AAPC2003-2012 = 1.76, 95% CI [0.23-3.32]). There was an overall decreasing trend of mortality. However, increased mortality was observed in two countries: Ecuador for boys (AAPC2007-2016 = 1.72, 95% CI [0.27-3.19]) and Austria for girls (AAPC2008-2017 = 4.11, 95% CI [0.38-7.98]). CONCLUSIONS The largest mortality and mortality to incidence ratio of childhood cancer were found in low-income countries. There was a substantial increasing trend of childhood cancer incidence, while overall its mortality has been decreasing over the past decade. More studies are needed to confirm the drivers behind these epidemiologic trends.
Collapse
Affiliation(s)
- Junjie Huang
- The Jockey Club School of Public Health and Primary Care, Faculty of MedicineChinese University of Hong KongHong KongSARChina
| | - Sze Chai Chan
- The Jockey Club School of Public Health and Primary Care, Faculty of MedicineChinese University of Hong KongHong KongSARChina
| | - Chun Ho Ngai
- The Jockey Club School of Public Health and Primary Care, Faculty of MedicineChinese University of Hong KongHong KongSARChina
| | - Veeleah Lok
- Department of Global Public Health, Karolinska InstituteKarolinska University HospitalStockholmSweden
| | - Lin Zhang
- School of Population and Global HealthThe University of MelbourneVictoriaAustralia,School of Public HealthThe Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina
| | - Don Eliseo Lucero‐Prisno
- Department of Global Health and DevelopmentLondon School of Hygiene and Tropical MedicineLondonUK
| | - Wanghong Xu
- School of Public HealthFudan UniversityShanghaiChina
| | - Zhi‐Jie Zheng
- Department of Global Health, School of Public HealthPeking UniversityBeijingChina
| | | | - Mellissa Withers
- Department of Population and Public Health Sciences, Institute for Global HealthUniversity of Southern CaliforniaLos AngelesCaliforniaUSA
| | - Martin C. S. Wong
- The Jockey Club School of Public Health and Primary Care, Faculty of MedicineChinese University of Hong KongHong KongSARChina,School of Public HealthThe Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina,Department of Global Health, School of Public HealthPeking UniversityBeijingChina
| | | |
Collapse
|
6
|
May-Hau DI, Bárcenas-López DA, Núñez-Enríquez JC, Bekker-Méndez VC, Beltrán-Anaya FO, Jiménez-Hernández E, Ortíz-Maganda MP, Guerra-Castillo FX, Medina-Sanson A, Flores-Lujano J, Martín-Trejo JA, Peñaloza-González JG, Velázquez-Aviña MM, Torres-Nava JR, Hernández-Echáurregui GA, Espinosa-Elizondo RM, Gutiérrez-Rivera MDL, Sanchez-Hernandez R, Pérez-Saldívar ML, Flores-Villegas LV, Merino-Pasaye LE, Duarte-Rodríguez DA, Mata-Rocha M, Sepúlveda-Robles OA, Rosas-Vargas H, Hidalgo-Miranda A, Mejía-Aranguré JM, Jiménez-Morales S. Underexpression of LINC00173 in TCF3/PBX1-Positive Cases Is Associated With Poor Prognosis in Children With B-Cell Precursor Acute Lymphoblastic Leukemia. Front Oncol 2022; 12:887766. [PMID: 35719952 PMCID: PMC9201104 DOI: 10.3389/fonc.2022.887766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Accepted: 04/21/2022] [Indexed: 11/13/2022] Open
Abstract
Background B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most frequent pediatric cancer worldwide. Despite improvements in treatment regimens, approximately 20% of the cases cannot be cured, highlighting the necessity for identifying new biomarkers to improve the current clinical and molecular risk stratification schemes. We aimed to investigate whether LINC00173 is a biomarker in ALL and to explore its expression level in other human cancer types. Methods A nested case-control study including Mexican children with BCP-ALL was conducted. LINC00173 expression was evaluated by qRT-PCR using hydrolysis probes. To validate our findings, RNA-seq expression data from BCP-ALL and normal tissues were retrieved from Therapeutically Applicable Research to Generate Effective Treatments (TARGET) and Genotype-Tissue Expression (GTEx) repositories, respectively. LINC00173 expression was also evaluated in solid tumors by downloading available data from The Cancer Genome Atlas (TCGA). Results A lower expression of LINC00173 in BCP-ALL cases compared to normal subjects was observed (p < 0.05). ALL patients who carry the TCF3/PBX1 fusion gene displayed lower expression of LINC00173 in contrast to other BCP-ALL molecular subtypes (p < 0.04). LINC00173 underexpression was associated with a high risk to relapse (HR = 1.946, 95% CI = 1.213-3.120) and die (HR = 2.073, 95% CI = 1.211-3.547). Patients with TCF3/PBX1 and underexpression of LINC00173 had the worst prognosis (DFS: HR = 12.24, 95% CI = 5.04-29.71; OS: HR = 11.19, 95% CI = 26-32). TCGA data analysis revealed that underexpression of LINC00173 is also associated with poor clinical outcomes in six new reported tumor types. Conclusion Our findings suggest that LINC00173 is a biomarker of poor prognosis in BCP-ALL and other types of cancer. We observed an association between the expression of LINC00173 and TCF3/PBX1 and the risk to relapse and die in BCP-ALL, which is worse in TCF3/PBX1-positive cases displaying underexpression of LINC00173. Experimental studies are needed to provide insight into the LINC00173 and TCF3/PBX relationship.
Collapse
Affiliation(s)
- Didier Ismael May-Hau
- Laboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City, Mexico.,Programa de Maestría en Investigación Clínica Experimental en Salud, Universidad Nacional Autónoma de Mexico, México City, Mexico
| | - Diego Alberto Bárcenas-López
- Laboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City, Mexico.,Programa de Doctorado, Posgrado en Ciencias Biológicas, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - Juan Carlos Núñez-Enríquez
- Unidad de Investigación Médica en Epidemiología Clínica, Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social, Mexico City, Mexico
| | - Vilma Carolina Bekker-Méndez
- Unidad de Investigación Médica en Inmunología e Infectología, Hospital de Infectología "Dr. Daniel Méndez Hernández", Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social, Mexico City, Mexico
| | - Fredy Omar Beltrán-Anaya
- Laboratorio de Epidemiología Clínica y Molecular, Facultad de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Mexico
| | - Elva Jiménez-Hernández
- Servicio de Hematología Pediátrica, Hospital General "Gaudencio González Garza", Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social, Mexico City, Mexico
| | - Mónica Patricia Ortíz-Maganda
- Unidad de Investigación Médica en Inmunología e Infectología, Hospital de Infectología "Dr. Daniel Méndez Hernández", Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social, Mexico City, Mexico
| | - Francisco Xavier Guerra-Castillo
- Unidad de Investigación Médica en Inmunología e Infectología, Hospital de Infectología "Dr. Daniel Méndez Hernández", Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social, Mexico City, Mexico
| | - Aurora Medina-Sanson
- Departamento de Hemato-Oncología, Hospital Infantil de México Federico Gómez, Mexico City, Mexico
| | - Janet Flores-Lujano
- Unidad de Investigación Médica en Epidemiología Clínica, Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social, Mexico City, Mexico
| | - Jorge Alfonso Martín-Trejo
- Servicio de Hematología Pediátrica, Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social, Mexico City, Mexico
| | | | | | - José Refugio Torres-Nava
- Servicio de Oncología, Hospital Pediátrico de Moctezuma, Secretaría de Salud de la Ciudad de México, Mexico City, Mexico
| | | | | | - María de Lourdes Gutiérrez-Rivera
- Servicio de Oncología Pediátrica, Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social, Mexico City, Mexico
| | - Rodrigo Sanchez-Hernandez
- Servicio de Oncología Pediátrica, Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social, Mexico City, Mexico
| | - María Luisa Pérez-Saldívar
- Unidad de Investigación Médica en Epidemiología Clínica, Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social, Mexico City, Mexico
| | - Luz Victoria Flores-Villegas
- Servicio de Hematología Pediátrica, Centro Médico Nacional "20 de Noviembre", Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City, Mexico
| | - Laura Elizabeth Merino-Pasaye
- Servicio de Hematología Pediátrica, Centro Médico Nacional "20 de Noviembre", Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City, Mexico
| | - David Aldebarán Duarte-Rodríguez
- Unidad de Investigación Médica en Epidemiología Clínica, Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social, Mexico City, Mexico
| | - Minerva Mata-Rocha
- Unidad de Investigación Médica en Genética Humana, Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social, Mexico City, Mexico
| | - Omar Alejandro Sepúlveda-Robles
- Unidad de Investigación Médica en Genética Humana, Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social, Mexico City, Mexico
| | - Haydeé Rosas-Vargas
- Unidad de Investigación Médica en Genética Humana, Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social, Mexico City, Mexico
| | - Alfredo Hidalgo-Miranda
- Laboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City, Mexico
| | - Juan Manuel Mejía-Aranguré
- Laboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City, Mexico.,Medicine Faculty, Universidad Autónoma de México, Mexico City, Mexico
| | - Silvia Jiménez-Morales
- Laboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City, Mexico
| |
Collapse
|
7
|
Major A, Palese M, Ermis E, James A, Villarroel M, Klussmann FA, Hessissen L, Geel J, Khan MS, Dalvi R, Sullivan M, Kearns P, Frazier AL, Pritchard-Jones K, Nakagawara A, Rodriguez-Galindo C, Volchenboum SL. Mapping Pediatric Oncology Clinical Trial Collaborative Groups on the Global Stage. JCO Glob Oncol 2022; 8:e2100266. [PMID: 35157510 PMCID: PMC8853619 DOI: 10.1200/go.21.00266] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
The global pediatric oncology clinical research landscape, particularly in Central and South America, Africa, and Asia, which bear the highest burden of global childhood cancer cases, is less characterized in the literature. Review of how existing pediatric cancer clinical trial groups internationally have been formed and how their research goals have been pursued is critical for building global collaborative research and data-sharing efforts, in line with the WHO Global Initiative for Childhood Cancer. Local stakeholder engagement is necessary to collaborate with global pediatric cancer trial groups.![]()
Collapse
Affiliation(s)
- Ajay Major
- Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
| | - Monica Palese
- Department of Pediatrics, University of Chicago, Chicago, IL
| | - Ebru Ermis
- Department of Pediatrics, University of Chicago, Chicago, IL
| | - Anthony James
- Department of Pediatrics, University of Chicago, Chicago, IL
| | - Milena Villarroel
- Grupo de América Latina de Oncología Pediátrica (GALOP), Hospital Luis Calvo Mackenna, National Pediatric Cancer Program (PINDA), Santiago, Chile
| | - Federico Antillon Klussmann
- National Unit of Pediatric Oncology, Francisco Marroquin University School of Medicine, Guatemala City, Guatemala
| | - Laila Hessissen
- Pediatric Hematology and Oncology, Mohammed V University of Rabat, Rabat, Morocco
| | - Jennifer Geel
- Faculty of Health Sciences, Division of Pediatric Haematology and Oncology, Department of Pediatrics and Child Health, University of the Witwatersrand, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa
| | - Muhammad Saghir Khan
- Department of Pediatrics, King Faisal Specialist Hospital and Research Center, Al Madinah, Saudi Arabia
| | - Rashmi Dalvi
- Bombay Hospital Institute of Medical Sciences and SRCC Children's Hospital, Mumbai, India
| | - Michael Sullivan
- Children's Cancer Centre, Royal Children's Hospital, Melbourne, Australia
| | - Pamela Kearns
- Cancer Research UK Clinical Trials Unit, National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom
| | | | - Kathy Pritchard-Jones
- UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom
| | | | | | | |
Collapse
|
8
|
Smith L, Stiller CA, Aitken JF, Hjalgrim LL, Johannesen T, Lahteenmaki P, McCabe MG, Phillips R, Pritchard-Jones K, Steliarova-Foucher E, Winther JF, Woods RR, Glaser AW, Feltbower RG. International variation in childhood cancer mortality rates from 2001 to 2015: Comparison of trends in the International Cancer Benchmarking Partnership countries. Int J Cancer 2022; 150:28-37. [PMID: 34449879 DOI: 10.1002/ijc.33774] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Revised: 07/14/2021] [Accepted: 07/21/2021] [Indexed: 11/10/2022]
Abstract
Despite improved survival rates, cancer remains one of the most common causes of childhood death. The International Cancer Benchmarking Partnership (ICBP) showed variation in cancer survival for adults. We aimed to assess and compare trends over time in cancer mortality between children, adolescents and young adults (AYAs) and adults in the six countries involved in the ICBP: United Kingdom, Denmark, Australia, Canada, Norway and Sweden. Trends in mortality between 2001 and 2015 in the six original ICBP countries were examined. Age standardised mortality rates (ASR per million) were calculated for all cancers, leukaemia, malignant and benign central nervous system (CNS) tumours, and non-CNS solid tumours. ASRs were reported for children (age 0-14 years), AYAs aged 15 to 39 years and adults aged 40 years and above. Average annual percentage change (AAPC) in mortality rates per country were estimated using Joinpoint regression. For all cancers combined, significant temporal reductions were observed in all countries and all age groups. However, the overall AAPC was greater for children (-2.9; 95% confidence interval = -4.0 to -1.7) compared to AYAs (-1.8; -2.1 to -1.5) and adults aged >40 years (-1.5; -1.6 to -1.4). This pattern was mirrored for leukaemia, CNS tumours and non-CNS solid tumours, with the difference being most pronounced for leukaemia: AAPC for children -4.6 (-6.1 to -3.1) vs AYAs -3.2 (-4.2 to -2.1) and over 40s -1.1 (-1.3 to -0.8). AAPCs varied between countries in children for all cancers except leukaemia, and in adults over 40 for all cancers combined, but not in subgroups. Improvements in cancer mortality rates in ICBP countries have been most marked among children aged 0 to 14 in comparison to 15 to 39 and over 40 year olds. This may reflect better care, including centralised service provision, treatment protocols and higher trial recruitment rates in children compared to older patients.
Collapse
Affiliation(s)
- Lesley Smith
- Leeds Institute for Data Analytics, School of Medicine, University of Leeds, Leeds, UK
| | - Charles A Stiller
- National Cancer Registration and Analysis Service, Public Health England, London, UK
| | - Joanne F Aitken
- School of Public Health, The University of Queensland, Brisbane, Queensland, Australia
- Cancer Council Queensland, Brisbane, Queensland, Australia
| | - Lisa L Hjalgrim
- Department of Pediatric Hematology/Oncology, University Hospital of Copenhagen, Copenhagen, Denmark
| | - Tom Johannesen
- Registry Department, Norwegian Cancer Registry, Oslo, Norway
| | - Paivi Lahteenmaki
- Swedish Childhood Cancer Registry, Karolinska Institute, Stockholm, Sweden
- Department of Pediatric and Adolecent Medicine, University of Turku, Turku, Finland
| | - Martin G McCabe
- Division of Cancer Sciences, University of Manchester, Manchester, UK
| | - Robert Phillips
- Centre for Reviews and Dissemination, University of York, York, UK
| | - Kathy Pritchard-Jones
- UCL Great Ormond Street Institute of Child Health, University College London, London, UK
| | | | - Jeanette F Winther
- Childhood Cancer Research Group, Danish Cancer Society Research Center, Copenhagen, Denmark
- Department of Clinical Medicine, Faculty of Health, Aarhus University and University Hospital, Aarhus, Denmark
| | - Ryan R Woods
- BC Cancer Research Centre, Vancouver, British Columbia, Canada
- Faculty of Heath Sciences, Simon Fraser University, Vancouver, British Columbia, Canada
| | - Adam W Glaser
- Leeds Institute for Data Analytics, School of Medicine, University of Leeds, Leeds, UK
- Leeds Institute of Medical Research at St James's, School of Medicine, University of Leeds, Leeds, UK
| | - Richard G Feltbower
- Leeds Institute for Data Analytics, School of Medicine, University of Leeds, Leeds, UK
| |
Collapse
|
9
|
Malvezzi M, Santucci C, Alicandro G, Carioli G, Boffetta P, Ribeiro KB, Levi F, La Vecchia C, Negri E, Bertuccio P. Childhood cancer mortality trends in the Americas and Australasia: An update to 2017. Cancer 2021; 127:3445-3456. [PMID: 34043810 PMCID: PMC8453533 DOI: 10.1002/cncr.33642] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Revised: 03/19/2021] [Accepted: 04/26/2021] [Indexed: 12/26/2022]
Abstract
BACKGROUND Marked reductions in childhood cancer mortality occurred over the last decades in high-income countries and, to a lesser degree, in middle-income countries. This study aimed to monitor mortality trends in the Americas and Australasia, focusing on areas showing unsatisfactory trends. METHODS Age-standardized mortality rates per 100,000 children (aged 0-14 years) from 1990 to 2017 (or the last available calendar year) were computed for all neoplasms and 8 leading childhood cancers in countries from the Americas and Australasia, using data from the World Health Organization database. A joinpoint regression was used to identify changes in slope of mortality trends for all neoplasms, leukemia, and neoplasms of the central nervous system (CNS) for major countries. RESULTS Over the last decades, childhood cancer mortality continued to decrease by approximately 2% to 3% per year in Australasian countries (ie, Japan, Korea, and Australia), by approximately 1.5% to 2% in North America and Chile, and 1% in Argentina. Other Latin American countries did not show any substantial decrease. Leukemia mortality declined in most countries, whereas less favorable trends were registered for CNS neoplasms, particularly in Latin America. Around 2016, death rates from all neoplasms were 4 to 6 per 100,000 boys and 3 to 4 per 100,000 girls in Latin America, and 2 to 3 per 100,000 boys and approximately 2 per 100,000 girls in North America and Australasia. CONCLUSIONS Childhood cancer mortality trends declined steadily in North America and Australasia, whereas they were less favorable in most Latin American countries. Priority must be given to closing the gap by providing high-quality care for all children with cancer worldwide. LAY SUMMARY Advances in childhood cancer management have substantially improved the burden of these neoplasms over the past 40 years, particularly in high-income countries. This study aimed to monitor recent trends in America and Australasia using mortality data from the World Health Organization. Trends in childhood cancer mortality continued to decline in high-income countries by approximately 2% to 3% per year in Japan, Korea, and Australia, and 1% to 2% in North America. Only a few Latin American countries showed favorable trends, including Argentina, Chile, and Mexico, whereas other countries with limited resources still lagged behind.
Collapse
Affiliation(s)
- Matteo Malvezzi
- Department of Clinical Sciences and Community HealthUniversità degli Studi di MilanoMilanItaly
| | - Claudia Santucci
- Department of Clinical Sciences and Community HealthUniversità degli Studi di MilanoMilanItaly
| | - Gianfranco Alicandro
- Department of Pathophysiology and TransplantationUniversità degli Studi di MilanoMilanItaly
| | - Greta Carioli
- Department of Clinical Sciences and Community HealthUniversità degli Studi di MilanoMilanItaly
| | - Paolo Boffetta
- Stony Brook Cancer CenterStony Brook UniversityStony BrookNew York
- Department of Medical and Surgical SciencesUniversity of BolognaBolognaItaly
| | - Karina Braga Ribeiro
- Department of Collective HealthFaculdade de Ciências Médicas da Santa Casa de São PauloSão PauloBrazil
- Department of Pediatric OncologyHospital Santa Marcelina/TUCCASão PauloBrazil
| | - Fabio Levi
- Department of Epidemiology and Health Services ResearchCentre for Primary Care and Public Health (Unisanté)University of LausanneLausanneSwitzerland
| | - Carlo La Vecchia
- Department of Clinical Sciences and Community HealthUniversità degli Studi di MilanoMilanItaly
| | - Eva Negri
- Department of Clinical Sciences and Community HealthUniversità degli Studi di MilanoMilanItaly
| | - Paola Bertuccio
- Department of Biomedical and Clinical Sciences L. SaccoUniversità degli Studi di MilanoMilanItaly
| |
Collapse
|
10
|
Leukemia mortality in children from Latin America: trends and predictions to 2030. BMC Pediatr 2020; 20:511. [PMID: 33160309 PMCID: PMC7648388 DOI: 10.1186/s12887-020-02408-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/23/2020] [Accepted: 10/28/2020] [Indexed: 12/24/2022] Open
Abstract
Background Reports suggest that Latin American and Caribbean (LAC) countries have not reduced leukemia mortality compared to high-income countries. However, updated trends remain largely unknown in the region. Given that leukemia is the leading cause of cancer-related death in LAC children, we evaluated mortality trends in children (0-14y) from 15 LAC countries for the period 2000–2017 and predicted mortality to 2030. Methods We retrieved cancer mortality data using the World Health Organization Mortality Database. Mortality rates (standardized to the world standard SEGI population) were analyzed for 15 LAC countries. We evaluated the average mortality rates for the last 5 years (2013–2017). Joinpoint regression analysis was used to evaluate leukemia mortality trends and provide an estimated annual percent change (EAPC). Nordpred was utilized for the calculation of predictions until 2030. Results Between 2013 and 2017, the highest mortality rates were reported in Venezuela, Ecuador, Nicaragua, Mexico, and Peru. Upward mortality trends were reported in Nicaragua (EAPC by 2.9% in boys, and EAPC by 2.0% in girls), and Peru (EAPC by 1.4% in both sexes). Puerto Rico experienced large declines in mortality among both boys (EAPC by − 9.7%), and girls (EAPC by − 6.0%). Leukemia mortality will increase in Argentina, Ecuador, Guatemala, Panama, Peru, and Uruguay by 2030. Conclusion Leukemia mortality is predicted to increase in some LAC countries by 2030. Interventions to prevent this outcome should be tailor to reduce the socioeconomic inequalities and ensure universal healthcare coverage. Supplementary Information The online version contains supplementary material available at 10.1186/s12887-020-02408-y.
Collapse
|
11
|
van Heerden J, Kruger M. Management of neuroblastoma in limited-resource settings. World J Clin Oncol 2020; 11:629-643. [PMID: 32879849 PMCID: PMC7443833 DOI: 10.5306/wjco.v11.i8.629] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/28/2020] [Revised: 06/23/2020] [Accepted: 07/26/2020] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Neuroblastoma (NB) is a heterogeneous disease with variable outcomes among countries. Little is known about NB in low- and middle-income countries (LMICs).
AIM The aim of this review was to evaluate regional management protocols and challenges in treating NB in paediatric oncology units in LMICs compared to high-income countries (HICs).
METHODS PubMed, Global Health, Embase, SciELO, African Index Medicus and Google Scholar were searched for publications with keywords pertaining to NB, LMICs and outcomes. Only English language manuscripts and abstracts were included. A descriptive review was done, and tables illustrating the findings were constructed.
RESULTS Limited information beyond single-institution experiences regarding NB outcomes in LMICs was available. The disease characteristics varied among countries for the following variables: sex, age at presentation, MYCN amplification, stage and outcome. LMICs were found to be burdened with a higher percentage of stage 4 and high-risk NB compared to HICs. Implementation of evidence-based treatment protocols was still a barrier to care. Many socioeconomic variables also influenced the diagnosis, management and follow-up of patients with NB.
CONCLUSION Patients presented at a later age with more advanced disease in LMICs. Management was limited by the lack of resources and genetic studies for improved NB classification. Further research is needed to develop modified diagnostic and treatment protocols for LMICs in the face of limited resources.
Collapse
Affiliation(s)
- Jaques van Heerden
- Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town 8000, South Africa
- Department of Paediatric Haematology and Oncology, Antwerp University Hospital, Edegem 2650, Belgium
| | - Mariana Kruger
- Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town 8000, South Africa
| |
Collapse
|
12
|
de Oliveira MM, E Silva DRM, Ramos FR, Curado MP. Children and adolescents cancer incidence, mortality and survival a population-based study in Midwest of Brazil. Cancer Epidemiol 2020; 68:101795. [PMID: 32818795 DOI: 10.1016/j.canep.2020.101795] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2020] [Revised: 07/24/2020] [Accepted: 07/26/2020] [Indexed: 11/16/2022]
Abstract
OBJECTIVE To identify time trends in incidence, mortality and 5-year relative survival in children and adolescents with cancer in Goiania-Goias, Brazil, during the years of 1996-2012. METHODS Incidence and mortality age-standardized rates (ASR) were calculated, and trends were identified by determining the Average Annual Percentage Change (AAPC). Five-year relative survival were estimated. RESULTS The overall incidence ASR (1996-2012) was 164.2/1,000,000 in both genders. In boys was 176.6/1,000,000, in girls it was 151.8/1,000,000. Overall mortality ASR for both gender were 69.3/1,000,000. Incidence rates (AAPC: -0.5; 95 %CI: -2.4;1.4) and mortality rates (AAPC: 0.0; 95 %CI: -2.6;2;7) were stable in the period. Five-year relative survival for all cancers were 63.9 %, with the highest survival rates for retinobastoma (83.5 %), germ cell tumors (79.8 %), and lymphomas (72.7 %). It was observed an increase in survival in the period from de 62.8 % (1996 a 2003) to 65.0 % from 2004 to 2012. CONCLUSIONS Children and adolescent cancer incidence and mortality rates were higher in Goiania, but both are stable overall. The relative survival slighly improved in the period but remained lower mainly for leukemias.
Collapse
Affiliation(s)
- Max Moura de Oliveira
- Group of Epidemiology and Statistics on Cancer, International Research Center, A.C. Camargo Cancer Center, São Paulo, Brazil
| | | | | | - Maria Paula Curado
- Group of Epidemiology and Statistics on Cancer, International Research Center, A.C. Camargo Cancer Center, São Paulo, Brazil.
| |
Collapse
|
13
|
Childhood cancer mortality trends in Europe, 1990-2017, with focus on geographic differences. Cancer Epidemiol 2020; 67:101768. [DOI: 10.1016/j.canep.2020.101768] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2020] [Revised: 05/28/2020] [Accepted: 06/13/2020] [Indexed: 12/15/2022]
|
14
|
Lupo PJ, Spector LG. Cancer Progress and Priorities: Childhood Cancer. Cancer Epidemiol Biomarkers Prev 2020; 29:1081-1094. [DOI: 10.1158/1055-9965.epi-19-0941] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2019] [Revised: 12/18/2019] [Accepted: 03/09/2020] [Indexed: 11/16/2022] Open
|
15
|
Feliciano SVM, Santos MDO, Pombo-de-Oliveira MS, de Aquino JÂP, de Aquino TA, Arregi MMU, Antoniazzif BN, da Costa AM, Formigosa LAC, Laporte CA, Lima CA, Machado NC, de Oliveira JC, Pereira LD, de Souza A, Dos Santos CMA, de Souza PCF, Venezian DB. Incidence and mortality of myeloid malignancies in children, adolescents and Young adults in Brazil: A population-based study. Cancer Epidemiol 2019; 62:101583. [PMID: 31472325 DOI: 10.1016/j.canep.2019.101583] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2019] [Revised: 08/02/2019] [Accepted: 08/05/2019] [Indexed: 12/20/2022]
Abstract
BACKGROUND Myeloid malignancies (MM) are heterogeneous when it comes to incidence rates and pathogenesis. These variation rates are important to generate hypotheses on causal aetiology. This study aimed to describe incidence and mortality patterns of MM among children, adolescents and young adults (cAYA) in Brazil and to evaluate trends in incidence and mortality rate overtime. METHODS Data were extracted from a dataset of 15 Population-based Cancer Registries located in five Brazilian geographical regions and calculated by age-specific, crude, and age-standardized incidence (ASR) and mortality rates per million persons. Joinpoint regression analyses were performed for trends evaluations, regionally. Annual Percent Change (APC) and Average Annual Percent Change (AAPC) were also estimated. RESULTS The overall ASR for incidence and mortality of MM in Brazil was 14.57 and 8.83 per million, respectively. The AML (non-APL AML and APL) incidence rate is 8.18 per million, whereas other MM subtypes altogether have an incidence rate of 2.62 per million, and not otherwise specified (NOS) is 3.70 per million. The analysis of incidence trends (AAPC) showed a significant decline in Manaus (-5.6%) and São Paulo (-4.7%), and a significant increase was observed in Fortaleza (5.8%). Mortality trends steadily declined in all registries, with significant declines occurring in Goiânia (-1.5%), Belo Horizonte (-2.3%), São Paulo (-2.5%), Curitiba (-2.8%) and Porto Alegre (-4.1%). CONCLUSION Our findings showed differences in the incidence and mortality rates of MM in cAYA in Brazil, geographically. Infants-AML have the highest incidence within the cAYA population (17.42 per million). There was a substantial decrease in mortality rate observed, which was interpreted as an improvement in MM recognition and therapeutic approach.
Collapse
Affiliation(s)
- Suellen Valadares Moura Feliciano
- Programa de Hematologia-Oncologia Pediátrica - PHOP, Instituto Nacional de Câncer José Alencar Gomes da Silva, Rio de Janeiro, Brazil
| | - Marceli de Oliveira Santos
- Divisão de Vigilância e Análise de Situação, Coordenação de Prevenção e Vigilância, Instituto Nacional de Câncer José Alencar Gomes da Silva, Rio de Janeiro, Brazil
| | - Maria S Pombo-de-Oliveira
- Programa de Hematologia-Oncologia Pediátrica - PHOP, Instituto Nacional de Câncer José Alencar Gomes da Silva, Rio de Janeiro, Brazil.
| | | | | | - Miren Maite Uribe Arregi
- Secretaria de Saúde do Estado do Ceará, Registro de Câncer de Base Populacional de Fortaleza, Brazil
| | - Berenice Navarro Antoniazzif
- Secretaria Estadual de Saúde de Minas Gerais, Superintendência de Epidemiologia, Registro de Câncer de Base Populacional de Belo Horizonte, Brazil
| | - Allini Mafra da Costa
- Hospital de Câncer de Barretos, Fundação Pio XII, Registro de Câncer de Base Populacional de Barretos, Brazil
| | - Lucrecia Aline Cabral Formigosa
- Coordenação Estadual de Atenção Oncológica, Secretaria Estadual de Saúde do Pará, Registro de Câncer de Base Populacional de Belém, Brazil
| | - Cyntia Asturian Laporte
- Secretaria Municipal de Saúde de Curitiba, Registro de Câncer de Base Populacional de Curitiba, Brazil
| | - Carlos Anselmo Lima
- Secretaria Estadual de Saúde, Hospital Gov. João Alves Filho, Registro de Câncer de Base Populacional de Aracaju, Brazil
| | - Nayara Cabral Machado
- Fundação Centro de Controle de Oncologia, Registro de Câncer de Base Populacional de Manaus, Brazil
| | - José Carlo de Oliveira
- Associação de Combate ao Câncer de Goiás, Registro de Câncer de Base Populacional de Goiânia, Brazil
| | - Larissa Dell'Antonio Pereira
- Secretaria Estadual de Saúde do Espírito Santo, Registro de Câncer de Base Populacional de Espírito Santo, Brazil
| | - Adriana de Souza
- Faculdade de Saúde Pública da Universidade de São Paulo, Registro de Câncer de Base Populacional de São Paulo, Brazil
| | | | - Paulo Cesar Fernandes de Souza
- Secretaria de Estado de Saúde do Mato Grosso, Superintendência de Vigilância em Saúde, Registro de Câncer de Base Populacional de Cuiabá, Brazil
| | | |
Collapse
|
16
|
Núñez-Enríquez JC, Gil-Hernández AE, Jiménez-Hernández E, Fajardo-Gutiérrez A, Medina-Sansón A, Flores-Lujano J, Espinoza-Hernández LE, Duarte-Rodríguez DA, Amador-Sánchez R, Peñaloza-González JG, Torres-Nava JR, Espinosa-Elizondo RM, Flores-Villegas LV, Merino-Pasaye LE, Pérez-Saldivar ML, Dorantes-Acosta EM, Cortés-Herrera B, Solis-Labastida KA, Núñez-Villegas NN, Velázquez-Aviña MM, Rangel-López A, González-Ávila AI, Santillán-Juárez JD, García-Velázquez AJ, Jiménez-Morales S, Bekker-Méndez VC, Rosas-Vargas H, Mata-Rocha M, Sepúlveda-Robles OA, Martín-Trejo JA, Mejía-Aranguré JM. Overweight and obesity as predictors of early mortality in Mexican children with acute lymphoblastic leukemia: a multicenter cohort study. BMC Cancer 2019; 19:708. [PMID: 31319816 PMCID: PMC6639907 DOI: 10.1186/s12885-019-5878-8] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2018] [Accepted: 06/24/2019] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND Mexico City has one of the highest incidences and mortality rates of acute lymphoblastic leukemia (ALL) in the world and a high frequency of early relapses (17%) and early mortality (15%). Otherwise, childhood overweight and obesity are reaching epidemic proportions. They have been associated with poor outcomes in children with ALL. The aim of present study was to identify if overweight and obesity are predictors of early mortality and relapse in Mexican children with ALL. METHODS A multicenter cohort study was conducted. ALL children younger than 15 years old were included and followed-up during the first 24 months after diagnosis. Overweight and obesity were classified according World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) criteria. Early mortality and early relapses were the main outcomes. RESULTS A total of 1070 children were analyzed. Overweight/obesity at diagnosis were predictors of early mortality (WHO: HR = 1.4, 95%CI:1.0-2.0; CDC: HR = 1.6, 95%CI:1.1-2.3). However, no associations between overweight (WHO: HR = 1.5, 95%CI:0.9-2.5; CDC: HR = 1.0; 95% CI:0.6-1.6) and obesity (WHO: HR = 1.5, 95%CI:0.7-3.2; CDC: HR = 1.4; 95%CI:0.9-2.3) with early relapse were observed. CONCLUSIONS Overweight and obese patients embody a subgroup with high risk of dying during leukemia treatment.
Collapse
Affiliation(s)
- Juan Carlos Núñez-Enríquez
- Unidad de Investigación Médica en Epidemiologia Clínica, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | - Ana Elena Gil-Hernández
- Unidad de Investigación Médica en Epidemiologia Clínica, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | - Elva Jiménez-Hernández
- Servicio de Hematología Pediátrica, Hospital General "Gaudencio González Garza", Centro Médico Nacional "La Raza", IMSS, Mexico City, Mexico
| | - Arturo Fajardo-Gutiérrez
- Unidad de Investigación Médica en Epidemiologia Clínica, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | - Aurora Medina-Sansón
- Servicio de Hemato-Oncologia, Hospital Infantil de México Federico Gómez, Secretaria de Salud (SS), Mexico City, Mexico
| | - Janet Flores-Lujano
- Unidad de Investigación Médica en Epidemiologia Clínica, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | - Laura Eugenia Espinoza-Hernández
- Servicio de Hematología Pediátrica, Hospital General "Gaudencio González Garza", Centro Médico Nacional "La Raza", IMSS, Mexico City, Mexico
| | - David Aldebarán Duarte-Rodríguez
- Unidad de Investigación Médica en Epidemiologia Clínica, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | - Raquel Amador-Sánchez
- Servicio de Hematología Pediátrica, Hospital General Regional "Carlos McGregor Sánchez Navarro", IMSS, Mexico City, Mexico
| | | | - José Refugio Torres-Nava
- Servicio de Oncología, Hospital Pediátrico de Moctezuma, Secretaria de Salud de la Ciudad de México (SSCDMX), Mexico City, Mexico
| | | | - Luz Victoria Flores-Villegas
- Servicio de Hematología Pediátrica, Centro Médico Nacional "20 de Noviembre", Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico City, Mexico
| | - Laura Elizabeth Merino-Pasaye
- Servicio de Hematología Pediátrica, Centro Médico Nacional "20 de Noviembre", Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico City, Mexico
| | - María Luisa Pérez-Saldivar
- Unidad de Investigación Médica en Epidemiologia Clínica, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | - Elisa María Dorantes-Acosta
- Servicio de Hemato-Oncologia, Hospital Infantil de México Federico Gómez, Secretaria de Salud (SS), Mexico City, Mexico
| | | | - Karina Anastacia Solis-Labastida
- Servicio de Hematología Pediátrica UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", IMSS, Mexico City, Mexico
| | - Nora Nancy Núñez-Villegas
- Servicio de Hematología Pediátrica, Hospital General "Gaudencio González Garza", Centro Médico Nacional "La Raza", IMSS, Mexico City, Mexico
| | | | | | - Ana Itamar González-Ávila
- Servicio de Hematología Pediátrica, Hospital General Regional "Carlos McGregor Sánchez Navarro", IMSS, Mexico City, Mexico
| | | | | | - Silvia Jiménez-Morales
- Laboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico
| | - Vilma Carolina Bekker-Méndez
- Unidad de Investigación Médica en Inmunología e Infectología, Hospital de Infectología "Dr. Daniel Méndez Hernández", "La Raza", IMSS, Mexico City, Mexico
| | - Haydee Rosas-Vargas
- Unidad de Investigación en Genética Humana, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", IMSS, Mexico City, Mexico
| | - Minerva Mata-Rocha
- Unidad de Investigación en Genética Humana, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", IMSS, Mexico City, Mexico
| | - Omar Alejandro Sepúlveda-Robles
- Unidad de Investigación en Genética Humana, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", IMSS, Mexico City, Mexico
| | - Jorge Alfonso Martín-Trejo
- Servicio de Hematología Pediátrica UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", IMSS, Mexico City, Mexico.
| | - Juan Manuel Mejía-Aranguré
- Unidad de Investigación Médica en Epidemiologia Clínica, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico. .,Coordinación de Investigación en Salud, IMSS, Mexico City, Mexico.
| |
Collapse
|
17
|
Balmant NV, Reis RDS, Santos MDO, Maschietto M, de Camargo B. Incidence and mortality of bone cancer among children, adolescents and young adults of Brazil. Clinics (Sao Paulo) 2019; 74:e858. [PMID: 31090796 PMCID: PMC6536091 DOI: 10.6061/clinics/2019/e858] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/12/2018] [Accepted: 01/17/2019] [Indexed: 02/02/2023] Open
Abstract
OBJECTIVES Bone cancers occur frequently in children, adolescents, and young adults aging 15 to 29 years. Osteosarcoma and Ewing sarcoma are the most frequent subtypes in this population. The aim of this study was to describe incidence and mortality trends of bone cancers among Brazilian children, adolescents and young adults. METHODS Incidence information was obtained from 23 population-based cancer registries. Mortality data were extracted from the Atlas of Cancer Mortality from 1979 to 2013. Specific and adjusted rates per million were analyzed according to gender, morphology and age at diagnosis. Median rates were used as a measure of central tendency. Joinpoint regression was applied to analyze trends. RESULTS Median incidence rates were 5.74 and 11.25 cases per million in children and young adults respectively. Osteosarcoma in the 15-19 years aged group had the highest incidence rates. Stable incidence rates were observed among five registries in 0-14 year's age group. Four registries had a decreased incidence trend among adolescents and young adults. Median mortality rates were 1.22 and 5.07 deaths per million in children and young adults respectively. Increased mortality was observed on the North and Northeast regions. Decreased mortality trends were seen in the South (children) and Southeast (adolescents and young adults). CONCLUSION Osteosarcoma and Ewing Sarcoma are the most incident bone cancers in all Brazilian regions. Bone cancers showed incidence and mortality patterns variation within the geographic regions and across age groups, although not significant. Despite limitations, it is crucial to monitor cancer epidemiology trends across geographic Brazilian regions.
Collapse
Affiliation(s)
- Nathalie Vieira Balmant
- Instituto Nacional do Cancer, Rio de Janeiro, RJ, BR
- Centro de Pesquisa, Instituto Nacional de Cancer, Rio de Janeiro, RJ, BR
| | | | | | - Mariana Maschietto
- Laboratorio Nacional de Biociencias, Centro Nacional de Pesquisa em Energia e Materiais, Campinas, SP, BR
| | - Beatriz de Camargo
- Centro de Pesquisa, Instituto Nacional de Cancer, Rio de Janeiro, RJ, BR
- Corresponding author. E-mail:
| |
Collapse
|
18
|
Castro-Ríos A, Reyes-Morales H, Pelcastre BE, Rendón-Macías ME, Fajardo-Gutiérrez A. Socioeconomic inequalities in survival of children with acute lymphoblastic leukemia insured by social security in Mexico: a study of the 2007-2009 cohorts. Int J Equity Health 2019; 18:40. [PMID: 30832668 PMCID: PMC6399870 DOI: 10.1186/s12939-019-0940-3] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2018] [Accepted: 02/18/2019] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Although acute lymphoblastic leukemia (ALL) 5 years survival in minors has reached 90%, socioeconomic differences have been reported among and within countries. Within countries, the difference has been related to the socioeconomic status of the parents, even in the context of public health services with universal coverage. In Mexico, differences in the mortality of children with cancer have been reported among sociodemographic zones. The Instituto Mexicano del Seguro Social (IMSS), the country's main social security institution, has reported socioeconomic differences in life expectancy within its affiliated population. Here, the socioeconomic inequalities in the survival of children (< 15 years old) enrolled in the IMSS were analyzed. METHODS Five-year survival data were analyzed in cohorts of patients diagnosed with ALL during the period 2007-2009 in the two IMSS networks of medical services that serve 7 states of the central region of Mexico. A Cox proportional risk model was developed and adjusted for the socioeconomic characteristics of family, community of residence and for the clinical characteristics of the children. The slope of socioeconomic inequality of the probability of dying within five years after the diagnosis of ALL was estimated. RESULTS For the 294 patients studied, the 5 years survival rate was 53.7%; the median survival was 4.06 years (4.9 years for standard-risk diagnosis; 2.5 years for high-risk diagnosis). The attrition rate was 12%. The Cox model showed that children who had been IMSS-insured for less than half their lives had more than double the risk of dying than those who had been insured for their entire lives. CONCLUSIONS We did not find evidence of socioeconomic inequalities in the survival of children with ALL associated with family income, educational and occupational level of parents. However, we found a relevant gradient related social security protection: the longer children's life insured by social security, the higher their probability of surviving ALL was. These results add evidence of the effectiveness of social security, as a mechanism of wealth redistribution and a promoter of social mobility. Extending these social security benefits to the entire Mexican population could promote better health outcomes.
Collapse
Affiliation(s)
- Angélica Castro-Ríos
- Unidad de Investigación en Epidemiología Clínica, Hospital de Pediatría, Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social, Avenida Cuauhtémoc 330, Col. Doctores, Ciudad de México, Mexico
| | - Hortensia Reyes-Morales
- Centro de Investigación en Sistemas de Salud, Instituto Nacional de Salud Pública, Cuernavaca, Morelos Mexico
| | - Blanca E. Pelcastre
- Centro de Investigación en Sistemas de Salud, Instituto Nacional de Salud Pública, Cuernavaca, Morelos Mexico
| | - Mario E. Rendón-Macías
- Unidad de Investigación en Epidemiología Clínica, Hospital de Pediatría, Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social, Avenida Cuauhtémoc 330, Col. Doctores, Ciudad de México, Mexico
- Public Health Department, Universidad Panamericana, Ciudad de México, Mexico
| | - Arturo Fajardo-Gutiérrez
- Unidad de Investigación en Epidemiología Clínica, Hospital de Pediatría, Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social, Avenida Cuauhtémoc 330, Col. Doctores, Ciudad de México, Mexico
| |
Collapse
|
19
|
Al-Asadi JN, Ibrahim SJ. Childhood Cancer in Basrah, Iraq During 2012-2016: Incidence and Mortality. Asian Pac J Cancer Prev 2018; 19:2337-2341. [PMID: 30141312 PMCID: PMC6171401 DOI: 10.22034/apjcp.2018.19.8.2337] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Accepted: 07/26/2018] [Indexed: 12/24/2022] Open
Abstract
Background: Worldwide, childhood cancer is rare. In addition, a distinct variation in both incidence and type distribution was reported between countries. Aim: To estimate the incidence and mortality rates of childhood cancer in Basrah, Iraq during 2012-2016. Methods: This registry based descriptive study included children aged 0-14 years with primary cancer who were newly diagnosed in Basrah during 2012-2016. The types of malignant tumors were classified according to International Classification of Childhood Cancer, Version 3 (ICCC-3). The overall and specific incidence and mortality rates by age and sex were calculated per 100,000 population. Results: A total of 723 new cases of childhood cancer were registered during the five- year study period, with a male to-female ratio of 1.2/1. Children aged <4 years accounted for 43.1% of patients. The overall incidence rate was 13.74/100,000, and the age standardized incidence rate (ASIR) was 13.87/100,000. Boys showed higher incidence rate than girls (14.78 vs. 12.66/100,000). Leukemia was the most common type of childhood cancer accounting for 35.4%, followed by lymphoma (17.8%), and central nervous system tumors 11.9%. The overall cancer-specific mortality rate was 6.04/100,000 and the ASMR was 6.08/100,000 children. Conclusion: The incidence rate of childhood cancer in Basrah as well as the cancer type distribution was comparable to that reported for developing countries.
Collapse
Affiliation(s)
- Jasim N Al-Asadi
- Department of Family and Community Medicine, College of Medicine, Basrah University, Basrah, Iraq.
| | | |
Collapse
|
20
|
Rodriguez-Romo L, Olaya Vargas A, Gupta S, Shalkow-Klincovstein J, Vega-Vega L, Reyes-Lopez A, Cicero-Oneto C, Mejia-Arangure J, Gonzalez-Ramella O, Pineiro-Retif R, Lopez-Facundo A, de los Angeles Del Campo-Martinez M, Tejocote I, Brennan K, Booth CM. Delivery of Pediatric Cancer Care in Mexico: A National Survey. J Glob Oncol 2018; 4:1-12. [PMID: 30084750 PMCID: PMC6223522 DOI: 10.1200/jgo.17.00238] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose Limited data describe the delivery of pediatric cancer care in Mexico. We report a nationwide survey of pediatric cancer units. Methods An electronic survey was distributed to 74 pediatric cancer units in Mexico to describe case volumes; organization of care; and availability of medical/surgical specialists, supportive care, complex therapies, and diagnostic services. Centers were classified as low (< 30 new patients/year), medium (30 to 59/year) and high (≥ 60/year). Results Sixty-two centers completed the survey (response rate, 84%). The median annual new case volume per center was 50 (interquartile range [IQR], 23 to 81). Thirty-four percent (n = 21), 26% (n = 16), and 40% (n = 25) of units were low-, medium-, and high-volume centers, respectively. Treatment units reported a median of two pediatric oncologists (IQR, 2) and one pediatric hematologist (IQR, 1 to 2). Availability of medical and surgical subspecialists varied by center size, with substantially more specialist support at higher-volume centers ( P < .01). Multidisciplinary tumor boards are available at 29% (six of 21), 56% (nine of 16), and 76% (19 of 25) of low- to high-volume centers, respectively ( P = .005). Radiation and palliative care services are available at 42% (n = 26) and 63% (n = 36) of all centers, which did not vary by center volume. Educational support for hospitalized children and school reintegration programs are available at 56% (n = 36) and 58% (n = 36) of centers, respectively. One third (38% [n = 23]) of centers reported that at least one half of patients were lost to follow-up during the transition from pediatric to adult programs. Conclusion A large variation exists in annual case volumes across Mexican pediatric cancer centers. Additional efforts to increase access to multidisciplinary, supportive, and palliative care across all pediatric cancer units in Mexico are required.
Collapse
Affiliation(s)
- Laura Rodriguez-Romo
- Laura Rodriguez-Romo, Queen’s University; Kelly Brennan and Christopher M. Booth, Queen’s University Cancer Research Institute, Kingston; Sumit Gupta, The Hospital for Sick Children, Toronto, Ontario, Canada; Laura Rodriguez and Rafael Pineiro-Retif, Hospital Universitario de la Universidad Autónoma de Nuevo León, Nuevo León; Alberto Olaya Vargas and Jaime Shalkow-Klincovstein, Instituto Nacional de Pediatria; Alfonso Reyes-Lopez and Carlo Cicero-Oneto, Hospital Infantil de México; Juan Mejia-Arangure, Centro Médico Nacional Siglo XXI; Maria de los Angeles Del Campo-Martinez, Centro Médico Nacional La Raza, Mexico City; Lourdes Vega-Vega, Hospital Infantil Teletón de Oncología, Querétaro; Oscar Gonzalez-Ramella, Hospital Civil de Guadalajara, Guadalajara; Aracely Lopez-Facundo, Universidad Autónoma del Estado de México, México; and Isidoro Tejocote, Hospital para el Nino del Instituto Materno Infantil, México, México, Toluca, Mexico
| | - Alberto Olaya Vargas
- Laura Rodriguez-Romo, Queen’s University; Kelly Brennan and Christopher M. Booth, Queen’s University Cancer Research Institute, Kingston; Sumit Gupta, The Hospital for Sick Children, Toronto, Ontario, Canada; Laura Rodriguez and Rafael Pineiro-Retif, Hospital Universitario de la Universidad Autónoma de Nuevo León, Nuevo León; Alberto Olaya Vargas and Jaime Shalkow-Klincovstein, Instituto Nacional de Pediatria; Alfonso Reyes-Lopez and Carlo Cicero-Oneto, Hospital Infantil de México; Juan Mejia-Arangure, Centro Médico Nacional Siglo XXI; Maria de los Angeles Del Campo-Martinez, Centro Médico Nacional La Raza, Mexico City; Lourdes Vega-Vega, Hospital Infantil Teletón de Oncología, Querétaro; Oscar Gonzalez-Ramella, Hospital Civil de Guadalajara, Guadalajara; Aracely Lopez-Facundo, Universidad Autónoma del Estado de México, México; and Isidoro Tejocote, Hospital para el Nino del Instituto Materno Infantil, México, México, Toluca, Mexico
| | - Sumit Gupta
- Laura Rodriguez-Romo, Queen’s University; Kelly Brennan and Christopher M. Booth, Queen’s University Cancer Research Institute, Kingston; Sumit Gupta, The Hospital for Sick Children, Toronto, Ontario, Canada; Laura Rodriguez and Rafael Pineiro-Retif, Hospital Universitario de la Universidad Autónoma de Nuevo León, Nuevo León; Alberto Olaya Vargas and Jaime Shalkow-Klincovstein, Instituto Nacional de Pediatria; Alfonso Reyes-Lopez and Carlo Cicero-Oneto, Hospital Infantil de México; Juan Mejia-Arangure, Centro Médico Nacional Siglo XXI; Maria de los Angeles Del Campo-Martinez, Centro Médico Nacional La Raza, Mexico City; Lourdes Vega-Vega, Hospital Infantil Teletón de Oncología, Querétaro; Oscar Gonzalez-Ramella, Hospital Civil de Guadalajara, Guadalajara; Aracely Lopez-Facundo, Universidad Autónoma del Estado de México, México; and Isidoro Tejocote, Hospital para el Nino del Instituto Materno Infantil, México, México, Toluca, Mexico
| | - Jaime Shalkow-Klincovstein
- Laura Rodriguez-Romo, Queen’s University; Kelly Brennan and Christopher M. Booth, Queen’s University Cancer Research Institute, Kingston; Sumit Gupta, The Hospital for Sick Children, Toronto, Ontario, Canada; Laura Rodriguez and Rafael Pineiro-Retif, Hospital Universitario de la Universidad Autónoma de Nuevo León, Nuevo León; Alberto Olaya Vargas and Jaime Shalkow-Klincovstein, Instituto Nacional de Pediatria; Alfonso Reyes-Lopez and Carlo Cicero-Oneto, Hospital Infantil de México; Juan Mejia-Arangure, Centro Médico Nacional Siglo XXI; Maria de los Angeles Del Campo-Martinez, Centro Médico Nacional La Raza, Mexico City; Lourdes Vega-Vega, Hospital Infantil Teletón de Oncología, Querétaro; Oscar Gonzalez-Ramella, Hospital Civil de Guadalajara, Guadalajara; Aracely Lopez-Facundo, Universidad Autónoma del Estado de México, México; and Isidoro Tejocote, Hospital para el Nino del Instituto Materno Infantil, México, México, Toluca, Mexico
| | - Lourdes Vega-Vega
- Laura Rodriguez-Romo, Queen’s University; Kelly Brennan and Christopher M. Booth, Queen’s University Cancer Research Institute, Kingston; Sumit Gupta, The Hospital for Sick Children, Toronto, Ontario, Canada; Laura Rodriguez and Rafael Pineiro-Retif, Hospital Universitario de la Universidad Autónoma de Nuevo León, Nuevo León; Alberto Olaya Vargas and Jaime Shalkow-Klincovstein, Instituto Nacional de Pediatria; Alfonso Reyes-Lopez and Carlo Cicero-Oneto, Hospital Infantil de México; Juan Mejia-Arangure, Centro Médico Nacional Siglo XXI; Maria de los Angeles Del Campo-Martinez, Centro Médico Nacional La Raza, Mexico City; Lourdes Vega-Vega, Hospital Infantil Teletón de Oncología, Querétaro; Oscar Gonzalez-Ramella, Hospital Civil de Guadalajara, Guadalajara; Aracely Lopez-Facundo, Universidad Autónoma del Estado de México, México; and Isidoro Tejocote, Hospital para el Nino del Instituto Materno Infantil, México, México, Toluca, Mexico
| | - Alfonso Reyes-Lopez
- Laura Rodriguez-Romo, Queen’s University; Kelly Brennan and Christopher M. Booth, Queen’s University Cancer Research Institute, Kingston; Sumit Gupta, The Hospital for Sick Children, Toronto, Ontario, Canada; Laura Rodriguez and Rafael Pineiro-Retif, Hospital Universitario de la Universidad Autónoma de Nuevo León, Nuevo León; Alberto Olaya Vargas and Jaime Shalkow-Klincovstein, Instituto Nacional de Pediatria; Alfonso Reyes-Lopez and Carlo Cicero-Oneto, Hospital Infantil de México; Juan Mejia-Arangure, Centro Médico Nacional Siglo XXI; Maria de los Angeles Del Campo-Martinez, Centro Médico Nacional La Raza, Mexico City; Lourdes Vega-Vega, Hospital Infantil Teletón de Oncología, Querétaro; Oscar Gonzalez-Ramella, Hospital Civil de Guadalajara, Guadalajara; Aracely Lopez-Facundo, Universidad Autónoma del Estado de México, México; and Isidoro Tejocote, Hospital para el Nino del Instituto Materno Infantil, México, México, Toluca, Mexico
| | - Carlo Cicero-Oneto
- Laura Rodriguez-Romo, Queen’s University; Kelly Brennan and Christopher M. Booth, Queen’s University Cancer Research Institute, Kingston; Sumit Gupta, The Hospital for Sick Children, Toronto, Ontario, Canada; Laura Rodriguez and Rafael Pineiro-Retif, Hospital Universitario de la Universidad Autónoma de Nuevo León, Nuevo León; Alberto Olaya Vargas and Jaime Shalkow-Klincovstein, Instituto Nacional de Pediatria; Alfonso Reyes-Lopez and Carlo Cicero-Oneto, Hospital Infantil de México; Juan Mejia-Arangure, Centro Médico Nacional Siglo XXI; Maria de los Angeles Del Campo-Martinez, Centro Médico Nacional La Raza, Mexico City; Lourdes Vega-Vega, Hospital Infantil Teletón de Oncología, Querétaro; Oscar Gonzalez-Ramella, Hospital Civil de Guadalajara, Guadalajara; Aracely Lopez-Facundo, Universidad Autónoma del Estado de México, México; and Isidoro Tejocote, Hospital para el Nino del Instituto Materno Infantil, México, México, Toluca, Mexico
| | - Juan Mejia-Arangure
- Laura Rodriguez-Romo, Queen’s University; Kelly Brennan and Christopher M. Booth, Queen’s University Cancer Research Institute, Kingston; Sumit Gupta, The Hospital for Sick Children, Toronto, Ontario, Canada; Laura Rodriguez and Rafael Pineiro-Retif, Hospital Universitario de la Universidad Autónoma de Nuevo León, Nuevo León; Alberto Olaya Vargas and Jaime Shalkow-Klincovstein, Instituto Nacional de Pediatria; Alfonso Reyes-Lopez and Carlo Cicero-Oneto, Hospital Infantil de México; Juan Mejia-Arangure, Centro Médico Nacional Siglo XXI; Maria de los Angeles Del Campo-Martinez, Centro Médico Nacional La Raza, Mexico City; Lourdes Vega-Vega, Hospital Infantil Teletón de Oncología, Querétaro; Oscar Gonzalez-Ramella, Hospital Civil de Guadalajara, Guadalajara; Aracely Lopez-Facundo, Universidad Autónoma del Estado de México, México; and Isidoro Tejocote, Hospital para el Nino del Instituto Materno Infantil, México, México, Toluca, Mexico
| | - Oscar Gonzalez-Ramella
- Laura Rodriguez-Romo, Queen’s University; Kelly Brennan and Christopher M. Booth, Queen’s University Cancer Research Institute, Kingston; Sumit Gupta, The Hospital for Sick Children, Toronto, Ontario, Canada; Laura Rodriguez and Rafael Pineiro-Retif, Hospital Universitario de la Universidad Autónoma de Nuevo León, Nuevo León; Alberto Olaya Vargas and Jaime Shalkow-Klincovstein, Instituto Nacional de Pediatria; Alfonso Reyes-Lopez and Carlo Cicero-Oneto, Hospital Infantil de México; Juan Mejia-Arangure, Centro Médico Nacional Siglo XXI; Maria de los Angeles Del Campo-Martinez, Centro Médico Nacional La Raza, Mexico City; Lourdes Vega-Vega, Hospital Infantil Teletón de Oncología, Querétaro; Oscar Gonzalez-Ramella, Hospital Civil de Guadalajara, Guadalajara; Aracely Lopez-Facundo, Universidad Autónoma del Estado de México, México; and Isidoro Tejocote, Hospital para el Nino del Instituto Materno Infantil, México, México, Toluca, Mexico
| | - Rafael Pineiro-Retif
- Laura Rodriguez-Romo, Queen’s University; Kelly Brennan and Christopher M. Booth, Queen’s University Cancer Research Institute, Kingston; Sumit Gupta, The Hospital for Sick Children, Toronto, Ontario, Canada; Laura Rodriguez and Rafael Pineiro-Retif, Hospital Universitario de la Universidad Autónoma de Nuevo León, Nuevo León; Alberto Olaya Vargas and Jaime Shalkow-Klincovstein, Instituto Nacional de Pediatria; Alfonso Reyes-Lopez and Carlo Cicero-Oneto, Hospital Infantil de México; Juan Mejia-Arangure, Centro Médico Nacional Siglo XXI; Maria de los Angeles Del Campo-Martinez, Centro Médico Nacional La Raza, Mexico City; Lourdes Vega-Vega, Hospital Infantil Teletón de Oncología, Querétaro; Oscar Gonzalez-Ramella, Hospital Civil de Guadalajara, Guadalajara; Aracely Lopez-Facundo, Universidad Autónoma del Estado de México, México; and Isidoro Tejocote, Hospital para el Nino del Instituto Materno Infantil, México, México, Toluca, Mexico
| | - Aracely Lopez-Facundo
- Laura Rodriguez-Romo, Queen’s University; Kelly Brennan and Christopher M. Booth, Queen’s University Cancer Research Institute, Kingston; Sumit Gupta, The Hospital for Sick Children, Toronto, Ontario, Canada; Laura Rodriguez and Rafael Pineiro-Retif, Hospital Universitario de la Universidad Autónoma de Nuevo León, Nuevo León; Alberto Olaya Vargas and Jaime Shalkow-Klincovstein, Instituto Nacional de Pediatria; Alfonso Reyes-Lopez and Carlo Cicero-Oneto, Hospital Infantil de México; Juan Mejia-Arangure, Centro Médico Nacional Siglo XXI; Maria de los Angeles Del Campo-Martinez, Centro Médico Nacional La Raza, Mexico City; Lourdes Vega-Vega, Hospital Infantil Teletón de Oncología, Querétaro; Oscar Gonzalez-Ramella, Hospital Civil de Guadalajara, Guadalajara; Aracely Lopez-Facundo, Universidad Autónoma del Estado de México, México; and Isidoro Tejocote, Hospital para el Nino del Instituto Materno Infantil, México, México, Toluca, Mexico
| | - Maria de los Angeles Del Campo-Martinez
- Laura Rodriguez-Romo, Queen’s University; Kelly Brennan and Christopher M. Booth, Queen’s University Cancer Research Institute, Kingston; Sumit Gupta, The Hospital for Sick Children, Toronto, Ontario, Canada; Laura Rodriguez and Rafael Pineiro-Retif, Hospital Universitario de la Universidad Autónoma de Nuevo León, Nuevo León; Alberto Olaya Vargas and Jaime Shalkow-Klincovstein, Instituto Nacional de Pediatria; Alfonso Reyes-Lopez and Carlo Cicero-Oneto, Hospital Infantil de México; Juan Mejia-Arangure, Centro Médico Nacional Siglo XXI; Maria de los Angeles Del Campo-Martinez, Centro Médico Nacional La Raza, Mexico City; Lourdes Vega-Vega, Hospital Infantil Teletón de Oncología, Querétaro; Oscar Gonzalez-Ramella, Hospital Civil de Guadalajara, Guadalajara; Aracely Lopez-Facundo, Universidad Autónoma del Estado de México, México; and Isidoro Tejocote, Hospital para el Nino del Instituto Materno Infantil, México, México, Toluca, Mexico
| | - Isidoro Tejocote
- Laura Rodriguez-Romo, Queen’s University; Kelly Brennan and Christopher M. Booth, Queen’s University Cancer Research Institute, Kingston; Sumit Gupta, The Hospital for Sick Children, Toronto, Ontario, Canada; Laura Rodriguez and Rafael Pineiro-Retif, Hospital Universitario de la Universidad Autónoma de Nuevo León, Nuevo León; Alberto Olaya Vargas and Jaime Shalkow-Klincovstein, Instituto Nacional de Pediatria; Alfonso Reyes-Lopez and Carlo Cicero-Oneto, Hospital Infantil de México; Juan Mejia-Arangure, Centro Médico Nacional Siglo XXI; Maria de los Angeles Del Campo-Martinez, Centro Médico Nacional La Raza, Mexico City; Lourdes Vega-Vega, Hospital Infantil Teletón de Oncología, Querétaro; Oscar Gonzalez-Ramella, Hospital Civil de Guadalajara, Guadalajara; Aracely Lopez-Facundo, Universidad Autónoma del Estado de México, México; and Isidoro Tejocote, Hospital para el Nino del Instituto Materno Infantil, México, México, Toluca, Mexico
| | - Kelly Brennan
- Laura Rodriguez-Romo, Queen’s University; Kelly Brennan and Christopher M. Booth, Queen’s University Cancer Research Institute, Kingston; Sumit Gupta, The Hospital for Sick Children, Toronto, Ontario, Canada; Laura Rodriguez and Rafael Pineiro-Retif, Hospital Universitario de la Universidad Autónoma de Nuevo León, Nuevo León; Alberto Olaya Vargas and Jaime Shalkow-Klincovstein, Instituto Nacional de Pediatria; Alfonso Reyes-Lopez and Carlo Cicero-Oneto, Hospital Infantil de México; Juan Mejia-Arangure, Centro Médico Nacional Siglo XXI; Maria de los Angeles Del Campo-Martinez, Centro Médico Nacional La Raza, Mexico City; Lourdes Vega-Vega, Hospital Infantil Teletón de Oncología, Querétaro; Oscar Gonzalez-Ramella, Hospital Civil de Guadalajara, Guadalajara; Aracely Lopez-Facundo, Universidad Autónoma del Estado de México, México; and Isidoro Tejocote, Hospital para el Nino del Instituto Materno Infantil, México, México, Toluca, Mexico
| | - Christopher M. Booth
- Laura Rodriguez-Romo, Queen’s University; Kelly Brennan and Christopher M. Booth, Queen’s University Cancer Research Institute, Kingston; Sumit Gupta, The Hospital for Sick Children, Toronto, Ontario, Canada; Laura Rodriguez and Rafael Pineiro-Retif, Hospital Universitario de la Universidad Autónoma de Nuevo León, Nuevo León; Alberto Olaya Vargas and Jaime Shalkow-Klincovstein, Instituto Nacional de Pediatria; Alfonso Reyes-Lopez and Carlo Cicero-Oneto, Hospital Infantil de México; Juan Mejia-Arangure, Centro Médico Nacional Siglo XXI; Maria de los Angeles Del Campo-Martinez, Centro Médico Nacional La Raza, Mexico City; Lourdes Vega-Vega, Hospital Infantil Teletón de Oncología, Querétaro; Oscar Gonzalez-Ramella, Hospital Civil de Guadalajara, Guadalajara; Aracely Lopez-Facundo, Universidad Autónoma del Estado de México, México; and Isidoro Tejocote, Hospital para el Nino del Instituto Materno Infantil, México, México, Toluca, Mexico
| |
Collapse
|
21
|
Silva MGP, Bedor CNG, Alencar KMDSA, Curado MP, Moura LTRD. Tendências da morbimortalidade por câncer infantojuvenil em um polo de fruticultura irrigada. ACTA ACUST UNITED AC 2018. [DOI: 10.1590/1414-462x201800010477] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Resumo Objetivo Descrever as tendências de morbimortalidade por câncer em jovens de 0 a 19 anos nos municípios de Petrolina (PE) e Juazeiro (BA). Método Série histórica de morbimortalidade por câncer infantojuvenil dos residentes em Petrolina (PE) e Juazeiro (BA), no período de 2004 a 2013, usando dados do Sistema de Informação de Internação Hospitalar e Sistema de Informação de Mortalidade. As taxas de internação e mortalidade foram padronizadas por idade, tendo sido realizada análise de tendências pelo modelo de regressão Joinpoint. Resultados As taxas de internação e de mortalidade foram mais altas em Petrolina comparadas com as de Juazeiro. Taxas de mortalidade acima de 60/1.000.0000 em ambos os municípios encontram-se acima das taxas de mortalidade brasileiras (40,28/1.000.000) e das taxas de mortalidade do Nordeste (35,62/1.000.000) para o período de 2001 a 2005. Conclusão Houve tendência de aumento significante das taxas de internação e aumento sem significância estatística das taxas de mortalidade nos dois municípios, o que pode estar relacionado à melhoria no acesso ao serviço especializado de oncologia pediátrica, ao diagnóstico tardio e à exposição ambiental a agrotóxicos.
Collapse
Affiliation(s)
| | | | | | - Maria Paula Curado
- Fundação Antônio Prudente, Brasil; International Prevention Research Institute, France
| | | |
Collapse
|
22
|
Kadam P, Van Saen D, Goossens E. Can mesenchymal stem cells improve spermatogonial stem cell transplantation efficiency? Andrology 2017; 5:2-9. [PMID: 27989021 DOI: 10.1111/andr.12304] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2016] [Revised: 10/04/2016] [Accepted: 10/20/2016] [Indexed: 12/11/2022]
Abstract
Improved treatments have led to an increased survival rate in cancer patients. However, in pre-pubertal boys, these gonadotoxic treatments can result in the depletion of the spermatogonial stem cell (SSC) pool causing lifelong infertility. SSC transplantation has been proposed as a promising technique to preserve the fertility of these patients. In mice, this technique has resulted in live-born offspring, but the efficiency of colonization remained low. This could be because of a deficient microenvironment, leading to apoptosis of the transplanted SSCs. Interestingly, mesenchymal stem cells (MSCs), being multipotent and easy to isolate and multiply in vitro, are nowadays successfully and widely used in regenerative medicine. Here, we shortly review the current understanding of MSC and SSC biology, and we hypothesize that a combined MSC-SSC transplantation might improve the efficiency of SSC colonization and differentiation as paracrine factors from MSCs may contribute to the SSC niche.
Collapse
Affiliation(s)
- P Kadam
- Biology of the Testis (BITE) Laboratory, Department of Reproduction, Genetics and Regenerative Medicine, Vrije Universiteit Brussel (VUB), Brussels, Belgium
| | - D Van Saen
- Biology of the Testis (BITE) Laboratory, Department of Reproduction, Genetics and Regenerative Medicine, Vrije Universiteit Brussel (VUB), Brussels, Belgium
| | - E Goossens
- Biology of the Testis (BITE) Laboratory, Department of Reproduction, Genetics and Regenerative Medicine, Vrije Universiteit Brussel (VUB), Brussels, Belgium
| |
Collapse
|
23
|
Núñez-Enríquez JC, Bárcenas-López DA, Hidalgo-Miranda A, Jiménez-Hernández E, Bekker-Méndez VC, Flores-Lujano J, Solis-Labastida KA, Martínez-Morales GB, Sánchez-Muñoz F, Espinoza-Hernández LE, Velázquez-Aviña MM, Merino-Pasaye LE, García Velázquez AJ, Pérez-Saldívar ML, Mojica-Espinoza R, Ramírez-Bello J, Jiménez-Morales S, Mejía-Aranguré JM. Gene Expression Profiling of Acute Lymphoblastic Leukemia in Children with Very Early Relapse. Arch Med Res 2017; 47:644-655. [PMID: 28476192 DOI: 10.1016/j.arcmed.2016.12.005] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2016] [Accepted: 11/24/2016] [Indexed: 10/19/2022]
Abstract
BACKGROUND AND AIMS Acute lymphoblastic leukemia (ALL) is the most common childhood cancer worldwide. Mexican patients have high mortality rates, low frequency of good prognosis biomarkers (i.e., ETV6-RUNX1) and a high proportion is classified at the time of diagnosis with a high risk to relapse according to clinical features. In addition, very early relapses are more frequently observed than in other populations. The aim of the study was to identify new potential biomarkers associated with very early relapse in Mexican ALL children through transcriptome analysis. METHODS Microarray gene expression profiling on bone marrow samples of 54 pediatric ALL patients, collected at time of diagnosis and/or at relapse, was performed. Eleven patients presented relapse within the first 18 months after diagnosis. Affymetrix Human Transcriptome Array 2.0 (HTA 2.0) was used to perform gene expression analysis. Annotation and functional enrichment analyses were carried out using Gene Ontology, KEGG pathway analysis and Ingenuity Pathway Analysis tools. RESULTS BLVRB, ZCCHC7, PAX5, EBF1, TMOD1 and BLNK were differentially expressed (fold-change >2.0 and p value <0.01) between relapsed and non-relapsed patients. Functional analysis of abnormally expressed genes revealed their important role in cellular processes related to the development of hematological diseases, cancer, cell death and survival and in cell-to-cell signaling interaction. CONCLUSIONS Our data support previous findings showing the relevance of PAX5, EBF1 and ZCCHC7 as potential biomarkers to identify a subgroup of ALL children in high risk to relapse.
Collapse
Affiliation(s)
- Juan Carlos Núñez-Enríquez
- Unidad de Investigación Médica en Epidemiología Clínica, UMAE Hospital de Pediatría, Centro Médico Nacional (CMN) "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | | | - Alfredo Hidalgo-Miranda
- Laboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico
| | - Elva Jiménez-Hernández
- Servicio de Hematología Pediátrica, Hospital General "Gaudencio González Garza", Centro Médico Nacional (CMN) "La Raza", IMSS, Mexico City, Mexico
| | - Vilma Carolina Bekker-Méndez
- Unidad de Investigación Médica en Inmunología e Infectología, Hospital de Infectología "Dr. Daniel Méndez Hernández", "La Raza", IMSS, Mexico City, Mexico
| | - Janet Flores-Lujano
- Unidad de Investigación Médica en Epidemiología Clínica, UMAE Hospital de Pediatría, Centro Médico Nacional (CMN) "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | - Karina Anastacia Solis-Labastida
- Servicio de Hematología Pediátrica, UMAE Hospital de Pediatría, Centro Médico Nacional (CMN) "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | - Gabriela Bibiana Martínez-Morales
- Unidad de Investigación Médica en Epidemiología Clínica, UMAE Hospital de Pediatría, Centro Médico Nacional (CMN) "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | - Fausto Sánchez-Muñoz
- Departamento de Inmunología, Instituto Nacional de Cardiología "Ignacio Chávez" (INCICh), Mexico City, Mexico
| | - Laura Eugenia Espinoza-Hernández
- Servicio de Hematología Pediátrica, Hospital General "Gaudencio González Garza", Centro Médico Nacional (CMN) "La Raza", IMSS, Mexico City, Mexico
| | | | - Laura Elizabeth Merino-Pasaye
- Servicio de Hematología Pediátrica, Centro Médico Nacional (CMN) "20 de Noviembre", Instituto de Seguridad Social al Servicio de los Trabajadores del Estado (ISSSTE), Mexico City, Mexico
| | | | - María Luisa Pérez-Saldívar
- Unidad de Investigación Médica en Epidemiología Clínica, UMAE Hospital de Pediatría, Centro Médico Nacional (CMN) "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
| | - Raúl Mojica-Espinoza
- Unidad de Genotipificación y Análisis de Expresión, Instituto Nacional de Medicina Genómica, Mexico City, Mexico
| | - Julián Ramírez-Bello
- Unidad de Investigación de Enfermedades Metabólicas y Endócrinas, Hospital Juárez de México, Mexico City, Mexico
| | - Silvia Jiménez-Morales
- Laboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico.
| | - Juan Manuel Mejía-Aranguré
- Unidad de Investigación Médica en Epidemiología Clínica, UMAE Hospital de Pediatría, Centro Médico Nacional (CMN) "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; Coordinación de Investigación en Salud, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico.
| | -
- Mexican Inter-Institutional Group for the Identification of the Causes of Childhood Leukaemia, Instituto Mexicano del Seguro Social, Instituto de Seguridad Social al Servicio de los Trabajadores del Estado, Secretaría de Salud, Secretaría de Salud del Gobierno del Distrito Federal, Mexico City, México
| |
Collapse
|
24
|
Rivera-Luna R, Zapata-Tarres M, Shalkow-Klincovstein J, Velasco-Hidalgo L, Olaya-Vargas A, Finkelstein-Mizrahi N, Cárdenas-Cardós R, Aguilar-Ortiz MR. The burden of childhood cancer in Mexico: Implications for low- and middle-income countries. Pediatr Blood Cancer 2017; 64. [PMID: 27905680 DOI: 10.1002/pbc.26366] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/28/2016] [Revised: 10/03/2016] [Accepted: 10/28/2016] [Indexed: 12/29/2022]
Abstract
In Mexico, childhood cancer incidence and mortality have increased in the last decade. Through government actions since 2005, the Popular Medical Insurance (PMI) program for childhood cancer was created. The objective of PMI was to offer early cancer diagnosis, standardized treatment regimens, and numerous pediatric oncology residency programs. It has also accredited 55 national hospitals for the care of these children. Current problems still present under the PMI include shortage of pediatric oncologists and nurses and high rate of abandonment of treatment. Our aim is to describe the current scenario of childhood cancer care in Mexico, especially from the perspective of the PMI and how it has impacted human resources, infrastructure, and medical education.
Collapse
Affiliation(s)
- Roberto Rivera-Luna
- Division of Pediatric Hem/Oncology, National Institute of Pediatrics (NIP), Mexico City, Mexico.,Program of the National Council for the Prevention and Treatment of Childhood Cancer, CENSIA, Mexico City, Mexico
| | - Marta Zapata-Tarres
- Department of Pediatric Oncology, National Institute of Pediatrics (NIP), Mexico City, Mexico
| | - Jaime Shalkow-Klincovstein
- Program of the National Council for the Prevention and Treatment of Childhood Cancer, CENSIA, Mexico City, Mexico
| | - Liliana Velasco-Hidalgo
- Department of Pediatric Oncology, National Institute of Pediatrics (NIP), Mexico City, Mexico
| | - Alberto Olaya-Vargas
- Bone Marrow Transplant Unit, National Institute of Pediatrics (NIP), Mexico City, Mexico
| | - Nicole Finkelstein-Mizrahi
- General Direction of Development of Health Services, Office of the Fund for Protection Against Catastrophic Expenses for Childhood Cancer from the Popular Medical Insurance, Mexico City, Mexico
| | - Rocío Cárdenas-Cardós
- Department of Pediatric Oncology, National Institute of Pediatrics (NIP), Mexico City, Mexico
| | - Marco R Aguilar-Ortiz
- Department of Pediatric Oncology, National Institute of Pediatrics (NIP), Mexico City, Mexico
| |
Collapse
|
25
|
Guimarães MD, Noschang J, Teixeira SR, Santos MK, Lederman HM, Tostes V, Kundra V, Oliveira AD, Hochhegger B, Marchiori E. Whole-body MRI in pediatric patients with cancer. Cancer Imaging 2017; 17:6. [PMID: 28187778 PMCID: PMC5303228 DOI: 10.1186/s40644-017-0107-7] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Accepted: 01/18/2017] [Indexed: 11/10/2022] Open
Abstract
Cancer is the leading cause of natural death in the pediatric populations of developed countries, yet cure rates are greater than 70% when a cancer is diagnosed in its early stages. Recent advances in magnetic resonance imaging methods have markedly improved diagnostic and therapeutic approaches, while avoiding the risks of ionizing radiation that are associated with most conventional radiological methods, such as computed tomography and positron emission tomography/computed tomography. The advent of whole-body magnetic resonance imaging in association with the development of metabolic- and function-based techniques has led to the use of whole-body magnetic resonance imaging for the screening, diagnosis, staging, response assessment, and post-therapeutic follow-up of children with solid sporadic tumours or those with related genetic syndromes. Here, the advantages, techniques, indications, and limitations of whole-body magnetic resonance imaging in the management of pediatric oncology patients are presented.
Collapse
Affiliation(s)
- Marcos Duarte Guimarães
- Department of Imaging, AC Camargo Cancer Center, Rua Prof. Antônio Prudente, 211, Liberdade, São Paulo/SP, 01509-010, Brazil.,Universidade Federal do Vale do São Francisco (UNIVASF), Av. José de Sá Maniçoba, Petrolina, PE, 56304-917, Brazil
| | - Julia Noschang
- Department of Imaging, AC Camargo Cancer Center, Rua Prof. Antônio Prudente, 211, Liberdade, Sao Paulo/SP, 01509-010, Brazil.
| | - Sara Reis Teixeira
- Division of Radiology, Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Av. Bandeirantes, 3900, Ribeirao Preto/ SP, 14049-090, Brazil
| | - Marcel Koenigkam Santos
- Division of Radiology, Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Av. Bandeirantes, 3900, Ribeirao Preto/ SP, 14049-090, Brazil
| | - Henrique Manoel Lederman
- Universidade Federal de São Paulo, Departamento de Diagnóstico Por Imagem, Disciplina de Diagnóstico por Imagem em Pediatria, Rua Napoleão de Barros, 800, Vila Clementino, Sao Paulo/SP, 04024002, Brazil
| | - Vivian Tostes
- Universidade Federal de São Paulo, Centro de Diagnóstico por Imagem do Instituto de Oncologia Pediátrica e Médica Radiologista do Centro de Diagnóstico por Imagem do Instituto de Oncologia Pediátrica, Rua Napoleão de Barros, 800, Vila Clementino, Sao Paulo/SP, 04024002, Brazil
| | - Vikas Kundra
- Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
| | - Alex Dias Oliveira
- Department of Imaging, AC Camargo Cancer Center, Rua Prof. Antônio Prudente, 211, Liberdade, Sao Paulo/SP, 01509-010, Brazil
| | - Bruno Hochhegger
- Department of Radiology, Universidade Federal de Ciências da Saúde de Porto Alegre, Rua Professor Anes Dias, 285, Centro Histórico, Porto Alegre/RS, 90020-090, Brazil
| | - Edson Marchiori
- Department of Radiology, Universidade Federal do Rio de Janeiro, Rua Thomaz Cameron, 438, Valparaíso, Petrópolis/RJ, 25685-129, Brazil
| |
Collapse
|
26
|
Brandalise SR, Viana MB, Pinheiro VRP, Mendonça N, Lopes LF, Pereira WV, Lee MLM, Pontes EM, Zouain-Figueiredo GP, Azevedo ACAC, Pimentel N, Fernandes MZ, Oliveira HM, Vianna SR, Scrideli CA, Werneck FA, Álvares MN, Boldrini É, Loggetto SR, Bruniera P, Mastellaro MJ, Souza EM, Araújo RA, Bandeira F, Tan DM, Carvalho NA, Salgado MAS. Shorter Maintenance Therapy in Childhood Acute Lymphoblastic Leukemia: The Experience of the Prospective, Randomized Brazilian GBTLI ALL-93 Protocol. Front Pediatr 2016; 4:110. [PMID: 27800472 PMCID: PMC5066157 DOI: 10.3389/fped.2016.00110] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/21/2016] [Accepted: 09/26/2016] [Indexed: 11/29/2022] Open
Abstract
AIM Maintenance therapy is an important phase of the childhood ALL treatment, requiring 2-year long therapy adherence of the patients and families. Weekly methotrexate with daily 6-mercaptopurine (6MP) constitutes the backbone of maintenance therapy. Reduction in the maintenance therapy could overweight problems related with poverty of children with ALL living in limited-income countries (LIC). OBJECTIVE To compare, prospectively, the EFS rates of children with ALL treated according to two maintenance regimens: 18 vs. 24 months duration. MATERIALS AND METHODS From October 1993 to September 1999, 867 consecutive untreated ALL patients <18 years of age were treated according to the Brazilian Cooperative Group for Childhood ALL Treatment (GBTLI) ALL-93 protocol. Risk classification was based exclusively on patient's age and leukocyte count (NCI risk group) and clinical extra medullary involvement of the disease. Data were analyzed by the intention-to-treat approach. RESULTS Fourteen patients (1.6%) were excluded: wrong diagnosis (n = 7) and previous corticosteroid (n = 7). Of the 853 eligible patients, 421 were randomly allocated, at study enrollment, to receive 18-month (group 1) and 432 to receive 24-month (group 2) maintenance therapy. Complete remission rate was achieved in 96% of the patients (817/853). Twenty-eight patients (3.4%) died during the induction phase. Thirty-four patients (4.0%) were lost to follow-up. The overall EFS was 66.1 ± 1.7% at 15 years. No difference was seen according to maintenance: EFS15y was 65.8 ± 2.3% (group 1) and 66.3 ± 2.3% (group 2; p = 0.79). No difference between regimens was detected after stratifying the analyses according to factors associated with adverse prognosis in this study (age group <1 year or >10 years and high WBC at diagnosis). Overall death in remission rate was 6.85% (56 patients). Deaths during maintenance were 13 in group 1 and 12 in group 2, all due to infection. Over 15 years of follow-up, two patients both from group 2 presented a second malignancy (Hodgkin's disease and thyroid carcinoma) after 8.3 and 11 years off therapy, respectively. CONCLUSION Six-month reduction of maintenance therapy in ALL children treated according to the GBTLI ALL-93 protocol provided the same overall outcome as 2-year duration regimen.
Collapse
Affiliation(s)
| | - Marcos B Viana
- Federal University of Minas Gerais , Belo Horizonte , Brazil
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Flávia Bandeira
- Hematology and Hemotherapy Foundation (HEMOPE) , Recife , Brazil
| | | | | | | |
Collapse
|
27
|
Yang L, Fujimoto J. Childhood cancer mortality in Japan, 1980-2013. BMC Cancer 2015; 15:446. [PMID: 26026605 PMCID: PMC4449967 DOI: 10.1186/s12885-015-1472-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2014] [Accepted: 05/26/2015] [Indexed: 11/09/2022] Open
Abstract
Background This study aimed to provide an updated analysis of childhood cancer mortality rates and long-term trends to 2013 to describe the current level of deaths and identify changes in recent decades. Methods Data on number of deaths from cancer in children aged under 15 years were derived from Vital Statistics in Japan and the World Health Organization (WHO) mortality database for comparison countries. Trends in mortality were examined by fitting a joinpoint regression model. Results For all cancers combined, the mortality rate during 2010–2013 was 19.9 per 1,000,000 population for boys and 17.5 for girls in Japan. Mortality from all cancers combined decreased significantly from 1980 to 2003 for boys and from 1980 to 2001 for girls. Afterwards, the rates remained stable for both sexes. Mortality from leukemia declined over the entire study period by 4.6 % per year (p <0.05) in boys and 4.3 % per year (p <0.05) in girls. For central nervous system (CNS) tumors, a slight increase in mortality was observed for both sexes, with a statistically significant annual percent change (APC) of 0.5 % (p <0.05) for boys and 0.6 % (p <0.05) for girls. Conclusions We provided updated information on recent trends of childhood cancer death. The establishment of a nationwide, childhood cancer registry is required in Japan. Moreover, trends in cancer mortality should be monitored continuously.
Collapse
Affiliation(s)
- Limin Yang
- Division of Allergy, Department of Medical Subspecialties, Medical Support Center for Japan Environment and Children's Study (JECS), National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan. .,Epidemiology and Clinical Research Center for Children's Cancer, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan.
| | - Junichiro Fujimoto
- Epidemiology and Clinical Research Center for Children's Cancer, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan.
| |
Collapse
|
28
|
Rivera-Luna R, Shalkow-Klincovstein J, Velasco-Hidalgo L, Cárdenas-Cardós R, Zapata-Tarrés M, Olaya-Vargas A, Aguilar-Ortiz MR, Altamirano-Alvarez E, Correa-Gonzalez C, Sánchez-Zubieta F, Pantoja-Guillen F. Descriptive Epidemiology in Mexican children with cancer under an open national public health insurance program. BMC Cancer 2014; 14:790. [PMID: 25355045 PMCID: PMC4228174 DOI: 10.1186/1471-2407-14-790] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2014] [Accepted: 10/23/2014] [Indexed: 11/10/2022] Open
Abstract
Background All the children registered at the National Council for the Prevention and Treatment of Childhood Cancer were analyzed. The rationale for this Federal Government Council is to financially support the treatment of all children registered into this system. All patients are within a network of 55 public certified hospitals nationwide. Methods In the current study, data from 2007 to 2012 are presented for all patients (0–18 years) with a pathological diagnosis of leukemia, lymphoma and solid tumors. The parameters analyzed were prevalence, incidence, mortality, and abandonment rate. Results A diagnosis of cancer was documented in 14,178 children. The incidence was of 156.9/million/year (2012). The median age was 4.9. The most common childhood cancer is leukemia, which occurs in 49.8% of patients (2007–2012); and has an incidence rate of 78.1/million/year (2012). The national mortality rate was 5.3/100,000 in 2012, however in the group between 15 to 18 years it reaches a level of 8.6. Conclusions The study demonstrates that there is a high incidence of childhood cancer in Mexico. In particular, the results reveal an elevated incidence and prevalence of leukemia especially from 0 to 4 years. Only 4.7% of these patients abandoned treatment. The clinical outcome for all of the children studied improved since the establishment of this national program.
Collapse
Affiliation(s)
- Roberto Rivera-Luna
- Head of the Division of Pediatric Hem/Oncology, National Institute of Pediatrics (NIP), Coordinator for the Technical Committee of the National Council for the Prevention and Treatment of Childhood Cancer, Mexico City, Mexico.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Epelman S, Magrath I. Planning cancer control—the view of an NGO. Lancet Oncol 2013; 14:388-90. [DOI: 10.1016/s1470-2045(13)70090-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
30
|
Childhood leukemia and lymphoma: time trends and factors affecting survival in five Southern and Eastern European Cancer Registries. Cancer Causes Control 2013; 24:1111-8. [PMID: 23529470 DOI: 10.1007/s10552-013-0188-y] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2012] [Accepted: 03/14/2013] [Indexed: 12/22/2022]
|
31
|
Magrath I, Steliarova-Foucher E, Epelman S, Ribeiro RC, Harif M, Li CK, Kebudi R, Macfarlane SD, Howard SC. Paediatric cancer in low-income and middle-income countries. Lancet Oncol 2013; 14:e104-16. [PMID: 23434340 DOI: 10.1016/s1470-2045(13)70008-1] [Citation(s) in RCA: 264] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Patterns of cancer incidence across the world have undergone substantial changes as a result of industrialisation and economic development. However, the economies of most countries remain at an early or intermediate stage of development-these stages are characterised by poverty, too few health-care providers, weak health systems, and poor access to education, modern technology, and health care because of scattered rural populations. Low-income and middle-income countries also have younger populations and therefore a larger proportion of children with cancer than high-income countries. Most of these children die from the disease. Chronic infections, which remain the most common causes of disease-related death in all except high-income countries, can also be major risk factors for childhood cancer in poorer regions. We discuss childhood cancer in relation to global development and propose strategies that could result in improved survival. Education of the public, more and better-trained health professionals, strengthened cancer services, locally relevant research, regional hospital networks, international collaboration, and health insurance are all essential components of an enhanced model of care.
Collapse
Affiliation(s)
- Ian Magrath
- International Network for Cancer Treatment and Research, Brussels, Belgium.
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Pérez-Cuevas R, Doubova SV, Zapata-Tarres M, Flores-Hernández S, Frazier L, Rodríguez-Galindo C, Cortes-Gallo G, Chertorivski-Woldenberg S, Muñoz-Hernández O. Scaling up cancer care for children without medical insurance in developing countries: The case of Mexico. Pediatr Blood Cancer 2013; 60:196-203. [PMID: 22887842 PMCID: PMC3561702 DOI: 10.1002/pbc.24265] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/10/2012] [Accepted: 07/02/2012] [Indexed: 11/26/2022]
Abstract
BACKGROUND In 2006, the Mexican government launched the Fund for Protection Against Catastrophic Expenditures (FPGC) to support financially healthcare of high cost illnesses. This study aimed at answering the question whether FPGC improved coverage for cancer care and to measure survival of FPGC affiliated children with cancer. PROCEDURE A retrospective cohort study (2006-2009) was conducted in 47 public hospitals. Information of children and adolescents with cancer was analyzed. The coverage was estimated in accordance with expected number of incident cases and those registered at FPGC. The survival was analyzed by using Kaplan-Meier survival curves and Cox proportional hazards regression modeling. RESULTS The study included 3,821 patients. From 2006 to 2009, coverage of new cancer cases increased from 3.3% to 55.3%. Principal diagnoses were acute lymphoblastic leukemia (ALL, 46.4%), central nervous system (CNS) tumors (8.2%), and acute myeloid leukemia (AML, 7.4%). The survival rates at 36 months were ALL (50%), AML (30.5%), Hodgkin lymphoma (74.5%), Non-Hodgkin lymphoma (40.1%), CNS tumors (32.8%), renal tumors (58.4%), bone tumors (33.4%), retinoblastoma (59.2%), and other solid tumors (52.6%). The 3-year overall survival rates varied among the regions; children between the east and south-southeast had the higher risks (hazard ratio 3.0; 95% CI: 2.3-3.9) and 2.4; 95% CI: 2.0-2.8) of death from disease when compared with those from the central region. CONCLUSION FPGC has increased coverage of cancer cases. Survival rates were different throughout the country. It is necessary to evaluate the effectiveness of this policy to increase access and identify opportunities to reduce the differences in survival.
Collapse
Affiliation(s)
- Ricardo Pérez-Cuevas
- Division of Social Protection and Health, Inter American Development Bank, Mexico City, Mexico.
| | - Svetlana V Doubova
- Epidemiology and Health Services Research Unit CMN Siglo XXI, Mexican Institute of Social SecurityMexico City, Mexico
| | - Marta Zapata-Tarres
- Oncology Department, Hospital Infantil de México Federico GomezMexico City, Mexico
| | - Sergio Flores-Hernández
- Center of Research on Population Health, National Institute of Public HealthCuernavaca, Morelos, Mexico
| | - Lindsay Frazier
- Harvard Medical School and Dana-Farber Cancer InstituteBoston, Massachusetts
| | | | | | | | | |
Collapse
|
33
|
Ferman S, Santos MDO, Ferreira JMDO, Reis RDS, Oliveira JFP, Pombo-de-Oliveira MS, Camargo BD. Childhood cancer mortality trends in Brazil, 1979-2008. Clinics (Sao Paulo) 2013; 68:219-24. [PMID: 23525319 PMCID: PMC3584264 DOI: 10.6061/clinics/2013(02)oa16] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/09/2012] [Accepted: 10/26/2012] [Indexed: 11/18/2022] Open
Abstract
OBJECTIVES Childhood cancer mortality has substantially declined worldwide as a result of significant advances in global cancer care. Because limited information is available in Brazil, we analyzed trends in childhood cancer mortality in five Brazilian regions over 29 years. METHODS Data from children 0-14 years old were extracted from the Health Mortality Information System for 1979 through 2008. Age-adjusted mortality rates, crude mortality rates, and age-specific mortality rates by geographic region of Brazil and for the entire country were analyzed for all cancers and leukemia. Mortality trends were evaluated for all childhood cancers and leukemia using joinpoint regression. RESULTS Mortality declined significantly for the entire period (1979-2008) for children with leukemia. Childhood cancer mortality rates declined in the South and Southeast, remained stable in the Middle West, and increased in the North and Northeast. Although the mortality rates did not unilaterally decrease in all regions, the age-adjusted mortality rates were relatively similar among the five Brazilian regions from 2006-2008. CONCLUSIONS Childhood cancer mortality declined 1.2 to 1.6% per year in the South and Southeast regions.
Collapse
Affiliation(s)
- Sima Ferman
- Pediatric Oncology Department, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brazil
| | | | | | | | | | | | | |
Collapse
|
34
|
Hernandez-Luna MA, Rocha-Zavaleta L, Vega MI, Huerta-Yepez S. Hypoxia inducible factor-1α induces chemoresistance phenotype in non-Hodgkin lymphoma cell line via up-regulation of Bcl-xL. Leuk Lymphoma 2012; 54:1048-55. [DOI: 10.3109/10428194.2012.733874] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
35
|
Youlden DR, Baade PD, Valery PC, Ward LJ, Green AC, Aitken JF. Childhood cancer mortality in Australia. Cancer Epidemiol 2012; 36:476-80. [DOI: 10.1016/j.canep.2012.06.001] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2012] [Revised: 06/05/2012] [Accepted: 06/05/2012] [Indexed: 10/28/2022]
|
36
|
Friedrich P, Ortiz R, Strait K, Fuentes S, Gamboa Y, Arambú I, Ah-Chu-Sanchez M, London W, Rodríguez-Galindo C, Antillón-Klussmann F, Báez F. Pediatric sarcoma in Central America: outcomes, challenges, and plans for improvement. Cancer 2012; 119:871-9. [PMID: 22972687 DOI: 10.1002/cncr.27816] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2012] [Revised: 08/01/2012] [Accepted: 08/06/2012] [Indexed: 01/26/2023]
Abstract
BACKGROUND Children with cancer in middle-income countries have inferior outcomes compared with similar children in high-income countries. The magnitude and drivers of this survival gap are not well understood. In the current report, the authors sought to describe patterns of clinical presentation, magnitude of treatment abandonment, and survival in children with sarcoma in Central America. METHODS A retrospective review was conducted of hospital-based registries from national pediatric oncology referral centers. Patients with newly diagnosed osteosarcoma, Ewing sarcoma, rhabdomyosarcoma (RMS), and soft tissue sarcoma (STS) between January 1, 2000 and December 31, 2009 were included. Survival analyses were performed first using standard definitions of overall survival (OS) and event-free survival (EFS) and then with abandonment included as an event (abandonment-sensitive OS and abandonment-sensitive EFS). RESULTS In total, 785 new cases of pediatric sarcoma were reported (264 diagnoses of osteosarcoma, 175 diagnoses of Ewing sarcoma, 240 diagnoses of RMS, and 106 diagnoses of STS). The rate of metastatic disease at presentation was high (osteosarcoma, 38%; Ewing sarcoma, 39%; RMS, 29%; and STS, 21%). The treatment abandonment rate also was high, particularly among patients with extremity bone sarcomas (osteosarcoma, 30%; Ewing sarcoma, 15%; RMS, 25%; and STS, 15%). Of 559 patients who experienced a first event, 59% had either recurrent or progressive disease. The 4-year OS rate (±standard error) was 40% ± 3%, and the EFS rate was 30% ± 2%; however, these rates decreased further to 31% ± 2% and 24% ± 2%, respectively, when abandonment was taken into account. CONCLUSIONS The current results indicated that high rates of metastases and treatment abandonment and difficulty with upfront treatment effectiveness are important contributors to the poor survival of children with pediatric sarcomas in Central America. Initiatives for early diagnosis, psychosocial support, quality improvement, and multidisciplinary care are warranted to improve outcomes.
Collapse
Affiliation(s)
- Paola Friedrich
- Department of Pediatric Hematology-Oncology, Dana-Farber/Children's Hospital Cancer Center, Boston, MA 02115, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Rivera-Luna R, Correa-González C, Altamirano-Alvarez E, Sánchez-Zubieta F, Cárdenas-Cardós R, Escamilla-Asian G, Olaya-Vargas A, Bautista-Marquez A, Aguilar-Romo M. Incidence of childhood cancer among Mexican children registered under a public medical insurance program. Int J Cancer 2012; 132:1646-50. [DOI: 10.1002/ijc.27771] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2012] [Accepted: 07/18/2012] [Indexed: 12/21/2022]
|
38
|
Wang N, Huang L, Wang D, Wang J, Jiang L, Zhou K, Yang Y, Xu D, Zhou J. Successful engraftment of human acute lymphoblastic leukemia cells in NOD/SCID mice via intrasplenic inoculation. Cancer Biol Ther 2012; 13:1158-64. [PMID: 22892848 DOI: 10.4161/cbt.21345] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Acute lymphoblastic leukemia (ALL) is a heterogeneous disorder, and primary drug resistance and relapse are thought to be the main causes for treatment failure in ALL patients. For these refractory or relapsed patients, there is an increasing demand to identify novel therapeutic approaches, which will highly rely on the use of xenotransplantation models in translational research. Given the critical role that the spleen plays in the hematopoiesis and lymphopoiesis in adult mice, intrasplenic inoculation of ALL cells into immunodeficient mice may represent a feasible route for leukemic xenotransplantation. In the present study, engraftments via intrasplenic inoculation in anti-mCD122 mAb conditioned NOD/SCID mice were achieved in 5 out of 11 cases, and the engrafted cells reconstituted a complete leukemic phenotype. The engrafted cells sustained the self-renewal capacity of leukemia-initiating cells as tested by serial xenotransplantation and can be used for evaluation of antileukemic drugs. These data suggest that the combination of intrasplenic inoculation and the targeted depletion of CD122(+) cells could provide a novel approach for the xenotransplantation of ALL cells in NOD/SCID mice. Furthermore, this model can be used for stem cell research, long-term analysis of engraftment kinetics and in vivo drug tests.
Collapse
Affiliation(s)
- Na Wang
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Cancer in childhood, adolescence, and young adults: a population-based study of changes in risk of cancer death during four decades in Norway. Cancer Causes Control 2012; 23:1297-305. [PMID: 22706693 DOI: 10.1007/s10552-012-0007-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2012] [Accepted: 05/30/2012] [Indexed: 01/02/2023]
Abstract
PURPOSE Cancer is one of the most common causes of death among young individuals. The purpose of this study was to explore the risk of early death (the first five years after diagnosis) among children (0-14 years), adolescents (15-19 years), and young adults (20-24 years) with cancer in Norway, born during 1965-1985. METHODS The overall and cancer-specific early deaths were explored by linking population-based national registers (including the Cancer Registry of Norway and the Cause of Death Registry) that include the entire population of Norway (approximately 1.3 million individuals). Hazard and sub-hazard ratios were estimated using Cox regression analyses and competing risk models. RESULTS A total of 5,828 individuals were diagnosed with cancer (56.3 % males). During follow-up, 1,415 individuals died from cancer (60.2 % males) within five years after diagnosis. The hazard ratio (HR) of overall death of the cancer patients relative to the general population decreased from 1965 (from HR, 385.8 (95 % confidence interval (CI): 335.3, 443.4) in 1965-74 to HR, 19.7 (CI: 9.3, 41.5) in 2005-09). Over all, there were fewer cancer-related deaths among female compared with male patients (sub-hazard ratio (SHR), 0.83 (CI: 0.74, 0.92)). Except for all hematopoietic malignancies, adolescents and young adult patients had lower risk of cancer death than children. CONCLUSION The difference in risk of cancer and overall deaths between the cancer patients and the general population has been substantially reduced since 1965.
Collapse
|
40
|
Bertuccio P, Bosetti C, Malvezzi M, Levi F, Chatenoud L, Negri E, Vecchia CL. Trends in mortality from leukemia in Europe: An update to 2009 and a projection to 2012. Int J Cancer 2012; 132:427-36. [DOI: 10.1002/ijc.27624] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2012] [Accepted: 04/23/2012] [Indexed: 11/11/2022]
|